The University of Chicago Header Logo

Michael Bishop

TitleProfessor
InstitutionUniversity of Chicago
DepartmentMedicine-Hematology and Oncology
AddressChicago IL 60637
vCardDownload vCard

    Collapse Research 
    Collapse research activities and funding
    Z01BC010698     (BISHOP, MICHAEL R)
    NIH
    Developing Immunoablative Regimens for the Engraftment of Allogeneic HSCT
    Role: Principal Investigator
    Z01SC010365     (BISHOP, MICHAEL R)
    NIH
    Optimizing the Graft-Versus-Tumor Effect in Allogeneic HSCT
    Role: Principal Investigator
    ZIABC010698     (BISHOP, MICHAEL R)
    NIH
    Developing Immunoablative Regimens for the Engraftment of Allogeneic HSCT
    Role: Principal Investigator
    ZIABC011239     (BISHOP, MICHAEL R)
    NIH
    Relapse after Allogeneic Hematopoietic Stem Cell Transplantation
    Role: Principal Investigator
    ZIASC010365     (BISHOP, MICHAEL R)
    NIH
    Optimizing the Graft-Versus-Tumor Effect in Allogeneic HSCT
    Role: Principal Investigator

    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. Kelly K, Cooperrider J, Bishop MR, Kosuri S, Jakubowiak A, Derman BA. Intrathecal chemotherapy for ciltacabtagene autoleucel-associated movement and neurocognitive toxicity. Blood Adv. 2025 May 07. PMID: 40334078.
      Citations:    Fields:    
    2. Cao G, Hu Y, Pan T, Tang E, Asby N, Althaus T, Wan J, Riedell PA, Bishop MR, Kline JP, Huang J. Two-stage CD8+ CAR T-cell differentiation in patients with large B-cell lymphoma. Nat Commun. 2025 May 06; 16(1):4205. PMID: 40328775; PMCID: PMC12055983.
      Citations:    Fields:    Translation:HumansCells
    3. Shah BD, Cassaday RD, Park JH, Houot R, Logan AC, Boissel N, Leguay T, Bishop MR, Topp MS, O'Dwyer KM, Tzachanis D, Arellano ML, Lin Y, Baer MR, Schiller GJ, Subklewe M, Abedi M, Minnema MC, Wierda WG, DeAngelo DJ, Stiff P, Jeyakumar D, Mao D, Adhikary S, Zhou L, Hadjivassileva T, Damico Khalid R, Ghobadi A, Oluwole OO. Three-year analysis of adult patients with relapsed or refractory B-cell acute lymphoblastic leukemia treated with brexucabtagene autoleucel in ZUMA-3. Leukemia. 2025 May; 39(5):1058-1068. PMID: 40108332; PMCID: PMC12055586.
      Citations:    Fields:    Translation:Humans
    4. Cao G, Hu Y, Pan T, Tang E, Asby N, Althaus T, Wan J, Riedell PA, Bishop MR, Kline JP, Huang J. Two-Stage CD8+ CAR T-Cell Differentiation in Patients with Large B-Cell Lymphoma. bioRxiv. 2025 Mar 15. PMID: 40161759; PMCID: PMC11952315.
      Citations:    
    5. Riedell PA, Grady CB, Nastoupil LJ, Luna De Abia A, Ahmed N, Maziarz RT, Hu M, Brower J, Hwang WT, Schuster SJ, Chen AI, Oluwole OO, Bachanova V, McGuirk JP, Perales MA, Bishop MR, Porter DL, Riedell PA, Grady CB, Nastoupil LJ, Luna A, Ahmed N, Maziarz RT, Hu M, Brower J, Hwang WT, Schuster SJ, Chen AI, Oluwole OO, Bachanova V, McGurik JP, Perales MA, Bishop MR, Porter DL. Lisocabtagene maraleucel for relapsed/refractory large B-cell lymphoma: a cell therapy consortium real-world analysis. Blood Adv. 2025 Mar 11; 9(5):1232-1241. PMID: 39657136; PMCID: PMC11993828.
      Citations: 1     Fields:    Translation:Humans
    6. Aldoss I, Roloff GW, Faramand RG, Kopmar NE, Lin C, Advani AS, Dekker SE, Gupta VK, O'Connor TE, Jeyakumar N, Muhsen IN, Valtis YK, Zhang A, Miller K, Sutherland KC, Dykes KC, Ahmed M, Chen EC, Zambrano H, Bradshaw D, Mercadal S, Schwartz MS, Tracy SI, Dholaria B, Kubiak MJ, Mukherjee A, Majhail NS, Battiwalla M, Mountjoy L, Malik SA, Mathews J, Shaughnessy PJ, Logan A, Ladha A, Stefan M, Guzowski C, Hoeg RT, Hilal T, Moore J, Connor M, O'Dwyer KM, Hill LC, Tsai SB, Sasine JP, Solh MM, Lee CJ, Kota V, Koura D, Veeraputhiran M, Blunk B, Oliai C, Leonard JT, Frey NV, Park JH, Luskin MR, Bachanova V, Galal A, Bishop MR, Stock W, Cassaday RD, Pullarkat VA, Shah BD, Muffly L, Aldoss I, Roloff GW, Faramand R, Kopmar NE, Lin C, Advani AS, Dekker SE, Gupta VK, O'Connor TE, Jeyakumar N, Muhsen IN, Valtis Y, Zhang A, Miller K, Sutherland K, Dykes KC, Ahmed M, Chen E, Zambrano H, Bradshaw D, Mercadal S, Schwartz M, Tracy S, Dholaria B, Kubiak M, Mukherjee A, Majhail N, Battiwalla M, Mountjoy L, Malik SA, Mathews J, Shaughnessy P, Logan AC, Ladha A, Stefan M, Guzowski C, Hoeg RT, Hilal T, Moore J, Connor M, O'Dwyer KM, Hill LC, Tsai SB, Sasine J, Solh MM, Lee CJ, Kota VK, Koura D, Veeraputhiran M, Blunk B, Oliai C, Leonard JT, Frey NV, Park JH, Luskin MR, Bachanova V, Galal A, Bishop MR, Stock W, Cassaday RD, Pullarkat V, Shah BD, Muffly LS. Impact of prior inotuzumab ozogamicin treatment on brexucabtagene autoleucel outcomes in adults with B-cell ALL. Blood Adv. 2024 Dec 10; 8(23):6139-6147. PMID: 39093952; PMCID: PMC11707416.
      Citations: 2     Fields:    Translation:Humans
    7. Bishop MR. Late complications and long-term care of adult CAR T-cell patients. Hematology Am Soc Hematol Educ Program. 2024 12 06; 2024(1):109-115. PMID: 39643985; PMCID: PMC11665735.
      Citations: 1     Fields:    Translation:Humans
    8. Roddie C, Sandhu KS, Tholouli E, Logan AC, Shaughnessy P, Barba P, Ghobadi A, Guerreiro M, Yallop D, Abedi M, Pantin JM, Yared JA, Beitinjaneh AM, Chaganti S, Hodby K, Menne T, Arellano ML, Malladi R, Shah BD, Mountjoy L, O'Dwyer KM, Peggs KS, Lao-Sirieix P, Zhang Y, Brugger W, Braendle E, Pule M, Bishop MR, DeAngelo DJ, Park JH, Jabbour E. Obecabtagene Autoleucel in Adults with B-Cell Acute Lymphoblastic Leukemia. N Engl J Med. 2024 Dec 12; 391(23):2219-2230. PMID: 39602653.
      Citations: 14     Fields:    Translation:HumansCTClinical Trials
    9. Roloff GW, Kosuri S, Nawas MT, DuVall AS, Patel AA, Riedell PA, Odenike O, Stock W, Larson RA, Bishop MR, Nunley E, Godley LA, Hathaway F, Del Gaudio D, Das S, Canham LE, Drazer MW. Expedited evaluation of hereditary hematopoietic malignancies in the setting of stem cell transplantation. Haematologica. 2024 Nov 01; 109(11):3739-3744. PMID: 38618681; PMCID: PMC11532700.
      Citations: 1     Fields:    
    10. Ahmed N, Wesson W, Lutfi F, Porter DL, Bachanova V, Nastoupil LJ, Perales MA, Maziarz RT, Brower J, Shah GL, Chen AI, Oluwole OO, Schuster SJ, Bishop MR, McGuirk JP, Riedell PA, Ahmed N, Wesson W, Lutfi F, Porter DL, Bachanova V, Nastoupil LJ, Perales MA, Maziarz RT, Brower J, Shah GL, Chen AI, Oluwole OO, Schuster SJ, Bishop MR, McGuirk JP, Riedell PA. Optimizing the post-CAR T monitoring period in recipients of axicabtagene ciloleucel, tisagenlecleucel, and lisocabtagene maraleucel. Blood Adv. 2024 10 22; 8(20):5346-5354. PMID: 39042880; PMCID: PMC11568755.
      Citations: 2     Fields:    Translation:Humans
    11. Holtzman NG, Curtis LM, Salit RB, Shaffer BC, Pirsl F, Ostojic A, Steinberg SM, Schulz E, Wilder JS, Hughes TE, Rose J, Memon S, Korngold R, Gea-Banacloche JC, Fowler DH, Hakim FT, Gress RE, Bishop MR, Pavletic SZ. High-dose alemtuzumab and cyclosporine vs tacrolimus, methotrexate, and sirolimus for chronic graft-versus-host disease prevention. Blood Adv. 2024 08 27; 8(16):4294-4310. PMID: 38669315; PMCID: PMC11372812.
      Citations: 3     Fields:    Translation:Humans
    12. Bishop MR. Into the (Second) Valley of Death, Rode the Six Hundred. Transplant Cell Ther. 2024 Aug; 30(8):732-733. PMID: 39089766.
      Citations:    Fields:    
    13. Yates SJ, Cursio JF, Artz A, Kordas K, Bishop MR, Derman BA, Kosuri S, Riedell PA, Kline J, Jakubowiak A, Mortel M, Johnson S, Nawas MT. Optimization of older adults by a geriatric assessment-guided multidisciplinary clinic before CAR T-cell therapy. Blood Adv. 2024 07 23; 8(14):3785-3797. PMID: 38810262; PMCID: PMC11298834.
      Citations: 2     Fields:    Translation:Humans
    14. Lee H, Amatya B, Villar VAM, Asico LD, Jeong JK, Feranil J, Moore SC, Zheng X, Bishop M, Gomes JP, Polzin J, Smeriglio N, de Castro PASV, Armando I, Felder RA, Hao L, Jose PA. Renal autocrine neuropeptide FF (NPFF) signaling regulates blood pressure. Sci Rep. 2024 07 04; 14(1):15407. PMID: 38965251; PMCID: PMC11224344.
      Citations: 1     Fields:    Translation:HumansAnimalsCells
    15. He G, Belmont E, Karrison T, Stock W, LaBelle JL, Kosuri S, Larson RA, Kline JP, Riedell PA, Nawas M, Bishop MR, Liu H. FLT3 inhibitor maintenance after allogeneic stem cell transplantation in FLT3-mutated acute myeloid leukemia (AML) patients. Ann Transl Med. 2024 Jun 10; 12(3):49. PMID: 38911560; PMCID: PMC11193555.
      Citations:    
    16. Betof Warner A, Hamid O, Komanduri K, Amaria R, Butler MO, Haanen J, Nikiforow S, Puzanov I, Sarnaik A, Bishop MR, Schoenfeld AJ. Expert consensus guidelines on management and best practices for tumor-infiltrating lymphocyte cell therapy. J Immunother Cancer. 2024 02 29; 12(2). PMID: 38423748; PMCID: PMC11005706.
      Citations: 13     Fields:    Translation:HumansCells
    17. Bishop MR, Kay GE. CAR T-cell therapy: A collaboration between authorized treatment centers and community oncologists. Semin Oncol. 2024 Jun-Aug; 51(3-4):87-94. PMID: 38531760.
      Citations: 1     Fields:    Translation:Humans
    18. Gagelmann N, Bishop M, Ayuk F, Bethge W, Glass B, Sureda A, Pasquini MC, Kröger N. Axicabtagene Ciloleucel versus Tisagenlecleucel for Relapsed or Refractory Large B Cell Lymphoma: A Systematic Review and Meta-Analysis. Transplant Cell Ther. 2024 Jun; 30(6):584.e1-584.e13. PMID: 38281590; PMCID: PMC11771143.
      Citations: 12     Fields:    Translation:Humans
    19. Veney D, Wei L, Toland AE, Presley CJ, Hampel H, Padamsee TJ, Lee CN, Irvin WJ, Bishop M, Kim J, Hovick SR, Senter L, Stover DG. A Video Intervention to Improve Patient Understanding of Tumor Genomic Testing in Patients with Cancer. medRxiv. 2023 Dec 05. PMID: 38106014; PMCID: PMC10723483.
      Citations:    
    20. Scordo M, Flynn JR, Gonen M, Devlin SM, Parascondola A, Tomas AA, Shouval R, Brower J, Porter DL, Schuster SJ, Bachanova V, Maakaron J, Maziarz RT, Chen AI, Nastoupil LJ, McGuirk JP, Oluwole OO, Ip A, Leslie LA, Bishop MR, Riedell PA, Perales MA. Identifying an optimal fludarabine exposure for improved outcomes after axi-cel therapy for aggressive B-cell non-Hodgkin lymphoma. Blood Adv. 2023 09 26; 7(18):5579-5585. PMID: 37522731; PMCID: PMC10514205.
      Citations: 9     Fields:    Translation:Humans
    21. Rojek AE, Kline JP, Feinberg N, Appelbaum DE, Pu Y, Derman BA, Jakubowiak A, Kosuri S, Liu H, Nawas MT, Smith SM, Bishop MR, Riedell PA. Optimization of Metabolic Tumor Volume as a Prognostic Marker in CAR T-Cell Therapy for Aggressive Large B-cell NHL. Clin Lymphoma Myeloma Leuk. 2024 02; 24(2):83-93. PMID: 37827881.
      Citations: 5     Fields:    Translation:Humans
    22. Bhaskar ST, Patel VG, Porter DL, Schuster SJ, Nastoupil LJ, Perales MA, Tomas AA, Bishop MR, McGuirk JP, Maziarz RT, Chen AI, Bachanova V, Maakaron JE, Riedell PA, Oluwole OO. Chimeric antigen receptor T-cell therapy yields similar outcomes in patients with and without cytokine release syndrome. Blood Adv. 2023 09 12; 7(17):4765-4772. PMID: 36508286; PMCID: PMC10468356.
      Citations: 6     Fields:    Translation:Humans
    23. Major A, Yu J, Shukla N, Che Y, Karrison TG, Treitman R, Kamdar MK, Haverkos BM, Godfrey J, Babcook MA, Voorhees TJ, Carlson S, Gaut D, Oliai C, Romancik JT, Winter AM, Hill BT, Bansal R, Villasboas Bisneto JC, Nizamuddin IA, Karmali R, Fitzgerald LA, Stephens DM, Pophali PA, Trabolsi A, Schatz JH, Hu M, Bachanova V, Slade MJ, Singh N, Ahmed N, McGuirk JP, Bishop MR, Riedell PA, Kline J. Efficacy of checkpoint inhibition after CAR-T failure in aggressive B-cell lymphomas: outcomes from 15 US institutions. Blood Adv. 2023 08 22; 7(16):4528-4538. PMID: 37026796; PMCID: PMC10425681.
      Citations: 16     Fields:    Translation:Humans
    24. Perissinotti AJ, Bishop MR, Bubalo J, Geyer MB, Goodrich A, Howard SC, Kula J, Mandayam S, Cairo MS, Pui CH. Expert consensus guidelines for the prophylaxis and management of tumor lysis syndrome in the United States: Results of a modified Delphi panel. Cancer Treat Rev. 2023 Nov; 120:102603. PMID: 37579533.
      Citations: 5     Fields:    
    25. Shah BD, Cassaday RD, Park JH, Houot R, Oluwole OO, Logan AC, Boissel N, Leguay T, Bishop MR, Topp MS, Tzachanis D, O'Dwyer KM, Arellano ML, Lin Y, Baer MR, Schiller GJ, Subklewe M, Abedi M, Minnema MC, Wierda WG, DeAngelo DJ, Stiff PJ, Jeyakumar D, Mao D, Adhikary S, Zhou L, Schuberth PC, Damico Khalid R, Ghobadia A. Impact of prior therapies and subsequent transplantation on outcomes in adult patients with relapsed or refractory B-cell acute lymphoblastic leukemia treated with brexucabtagene autoleucel in ZUMA-3. J Immunother Cancer. 2023 08; 11(8). PMID: 37648261; PMCID: PMC10471850.
      Citations: 11     Fields:    Translation:Humans
    26. Wudhikarn K, Tomas AA, Flynn JR, Devlin SM, Brower J, Bachanova V, Nastoupil LJ, McGuirk JP, Maziarz RT, Oluwole OO, Schuster SJ, Porter DL, Bishop MR, Riedell PA, Perales MA. Low toxicity and excellent outcomes in patients with DLBCL without residual lymphoma at the time of CD19 CAR T-cell therapy. Blood Adv. 2023 07 11; 7(13):3192-3198. PMID: 36355838; PMCID: PMC10338201.
      Citations: 15     Fields:    Translation:Humans
    27. Ahmed N, Wesson W, Mushtaq MU, Porter DL, Nasta SD, Brower J, Bachanova V, Hu M, Nastoupil LJ, Oluwole OO, Patel VG, Oliai C, Riedell PA, Bishop MR, Shah GL, Perales MA, Schachter L, Maziarz RT, McGuirk JP. Patient Characteristics and Outcomes of Outpatient Tisagenlecleucel Recipients for B Cell Non-Hodgkin Lymphoma. Transplant Cell Ther. 2023 07; 29(7):449.e1-449.e7. PMID: 37120134; PMCID: PMC11027185.
      Citations: 7     Fields:    Translation:Humans
    28. Godfrey J, Liu H, Yu J, Tallarico M, Curran E, Artz A, Riedell PA, Stock W, Karrison T, Fitzpatrick C, Venkataraman G, Cooper A, Smith SM, Bishop MR, Kline J. Pembrolizumab for the treatment of disease relapse after allogeneic hematopoietic stem cell transplantation. Blood Adv. 2023 03 28; 7(6):963-970. PMID: 35973200; PMCID: PMC10027501.
      Citations: 9     Fields:    Translation:HumansAnimals
    29. Frigault MJ, Bishop MR, Rosenblatt J, O'Donnell EK, Raje N, Cook D, Yee AJ, Logan E, Avigan DE, Jakubowiak A, Shaw K, Daley H, Nikiforow S, Griffin F, Cornwell C, Shen A, Heery C, Maus MV. Phase 1 study of CART-ddBCMA for the treatment of subjects with relapsed and refractory multiple myeloma. Blood Adv. 2023 03 14; 7(5):768-777. PMID: 35468618; PMCID: PMC9989524.
      Citations: 32     Fields:    Translation:HumansCellsCTClinical Trials
    30. Saygin C, Roloff G, Hahn CN, Chhetri R, Gill S, Elmariah H, Talati C, Nunley E, Gao G, Kim A, Bishop M, Kosuri S, Das S, Singhal D, Venugopal P, Homan CC, Brown A, Scott HS, Hiwase D, Godley LA. Allogeneic hematopoietic stem cell transplant outcomes in adults with inherited myeloid malignancies. Blood Adv. 2023 02 28; 7(4):549-554. PMID: 36001442; PMCID: PMC9979761.
      Citations: 22     Fields:    Translation:Humans
    31. Tran MC, Hasan Y, Wang A, Yenice K, Partouche J, Stock W, Larson RA, Kosuri S, LaBelle JL, Kline J, Riedell PA, Artz AS, Weichselbaum R, Bishop MR, Aydogan B, Liu H. A phase 1 trial utilizing TMI with fludarabine-melphalan in patients with hematologic malignancies undergoing second allo-SCT. Blood Adv. 2023 02 14; 7(3):285-292. PMID: 35851593; PMCID: PMC9898602.
      Citations: 2     Fields:    Translation:HumansCTClinical Trials
    32. Shah BD, Ghobadi A, Oluwole OO, Logan AC, Boissel N, Cassaday RD, Leguay T, Bishop MR, Topp MS, Tzachanis D, O'Dwyer KM, Arellano ML, Lin Y, Baer MR, Schiller GJ, Park JH, Subklewe M, Abedi M, Minnema MC, Wierda WG, DeAngelo DJ, Stiff P, Jeyakumar D, Dong J, Adhikary S, Zhou L, Schuberth PC, Faghmous I, Masouleh BK, Houot R. Two-year follow-up of KTE-X19 in patients with relapsed or refractory adult B-cell acute lymphoblastic leukemia in ZUMA-3 and its contextualization with SCHOLAR-3, an external historical control study. J Hematol Oncol. 2022 12 10; 15(1):170. PMID: 36494725; PMCID: PMC9734710.
      Citations: 29     Fields:    Translation:Humans
    33. Atkins MB, Abu-Sbeih H, Ascierto PA, Bishop MR, Chen DS, Dhodapkar M, Emens LA, Ernstoff MS, Ferris RL, Greten TF, Gulley JL, Herbst RS, Humphrey RW, Larkin J, Margolin KA, Mazzarella L, Ramalingam SS, Regan MM, Rini BI, Sznol M. Maximizing the value of phase III trials in immuno-oncology: A checklist from the Society for Immunotherapy of Cancer (SITC). J Immunother Cancer. 2022 09; 10(9). PMID: 36175037; PMCID: PMC9528604.
      Citations: 6     Fields:    Translation:Animals
    34. Jaeger U, Tam CS, Borchmann P, McGuirk JP, Johansen M, Waller EK, Jaglowski S, Andreadis C, Foley SR, Westin JR, Fleury I, Ho PJ, Mielke S, Teshima T, Salles G, Schuster SJ, He F, Maziarz RT, Mayer S, Makita S, Kersten MJ, Ghosh M, Wagner-Johnston N, Kato K, Corradini P, Goto H, Colicino S, Agarwal A, Lobetti-Bodoni C, Bishop MR. Long-term safety for patients with tisagenlecleucel-treated relapsed/refractory diffuse large B-cell lymphoma. Blood Adv. 2022 08 23; 6(16):4816-4820. PMID: 35687492; PMCID: PMC9631665.
      Citations: 7     Fields:    Translation:Humans
    35. Riedell PA, Hwang WT, Nastoupil LJ, Pennisi M, McGuirk JP, Maziarz RT, Bachanova V, Oluwole OO, Brower J, Flores OA, Ahmed N, Schachter L, Bharucha K, Dholaria BR, Schuster SJ, Perales MA, Bishop MR, Porter DL. Patterns of Use, Outcomes, and Resource Utilization among Recipients of Commercial Axicabtagene Ciloleucel and Tisagenlecleucel for Relapsed/Refractory Aggressive B Cell Lymphomas. Transplant Cell Ther. 2022 10; 28(10):669-676. PMID: 35850429; PMCID: PMC9547952.
      Citations: 27     Fields:    Translation:Humans
    36. Shah BD, Smith NJ, Feng C, Jeyakumar S, Castaigne JG, Faghmous I, Masouleh BK, Malone DC, Bishop MR. Cost-Effectiveness of KTE-X19 for Adults with Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia in the United States. Adv Ther. 2022 08; 39(8):3678-3695. PMID: 35727476; PMCID: PMC9309154.
      Citations:    Fields:    Translation:Humans
    37. Symes E, Wang P, Lager AM, Bishop MR, Aqil B, Venkataraman G. TP53/PLCG2-mutated diffuse large B-cell lymphoma richter transformation (DLBCL-RT) of CLL with unusual CD2 and PD-1 expression. Leuk Lymphoma. 2022 11; 63(11):2735-2738. PMID: 35719104.
      Citations:    Fields:    Translation:Humans
    38. Bishop MR. New hope to prevent ALL relapse after transplant. Blood. 2022 04 28; 139(17):2580-2581. PMID: 35482346.
      Citations: 1     Fields:    Translation:Humans
    39. Kott KA, Bishop M, Yang CHJ, Plasto TM, Cheng DC, Kaplan AI, Cullen L, Celermajer DS, Meikle PJ, Vernon ST, Figtree GA. Biomarker Development in Cardiology: Reviewing the Past to Inform the Future. Cells. 2022 02 08; 11(3). PMID: 35159397; PMCID: PMC8834296.
      Citations: 5     Fields:    Translation:Humans
    40. Bishop MR, Dickinson M, Purtill D, Barba P, Santoro A, Hamad N, Kato K, Sureda A, Greil R, Thieblemont C, Morschhauser F, Janz M, Flinn I, Rabitsch W, Kwong YL, Kersten MJ, Minnema MC, Holte H, Chan EHL, Martinez-Lopez J, Müller AMS, Maziarz RT, McGuirk JP, Bachy E, Le Gouill S, Dreyling M, Harigae H, Bond D, Andreadis C, McSweeney P, Kharfan-Dabaja M, Newsome S, Degtyarev E, Awasthi R, Del Corral C, Andreola G, Masood A, Schuster SJ, Jäger U, Borchmann P, Westin JR. Second-Line Tisagenlecleucel or Standard Care in Aggressive B-Cell Lymphoma. N Engl J Med. 2022 02 17; 386(7):629-639. PMID: 34904798.
      Citations: 193     Fields:    Translation:HumansCTClinical Trials
    41. Hu Y, Cao G, Chen X, Huang X, Asby N, Ankenbruck N, Rahman A, Thusu A, He Y, Riedell PA, Bishop MR, Schreiber H, Kline JP, Huang J. Antigen-Multimers: Specific, Sensitive, Precise, and Multifunctional High-Avidity CAR-Staining Reagents. Matter. 2021 Dec 01; 4(12):3917-3940. PMID: 34901832; PMCID: PMC8654235.
      Citations: 4     
    42. Bishop MR, Yuen C, Rezania K, Kelly T. Clinical predictors of chimeric antigen receptor T-cell therapy neurotoxicity: a single-center study. Immunotherapy. 2021 10; 13(15):1261-1269. PMID: 34558978.
      Citations: 2     Fields:    Translation:Humans
    43. Schuster SJ, Tam CS, Borchmann P, Worel N, McGuirk JP, Holte H, Waller EK, Jaglowski S, Bishop MR, Damon LE, Foley SR, Westin JR, Fleury I, Ho PJ, Mielke S, Teshima T, Janakiram M, Hsu JM, Izutsu K, Kersten MJ, Ghosh M, Wagner-Johnston N, Kato K, Corradini P, Martinez-Prieto M, Han X, Tiwari R, Salles G, Maziarz RT. Long-term clinical outcomes of tisagenlecleucel in patients with relapsed or refractory aggressive B-cell lymphomas (JULIET): a multicentre, open-label, single-arm, phase 2 study. Lancet Oncol. 2021 10; 22(10):1403-1415. PMID: 34516954.
      Citations: 233     Fields:    Translation:HumansCellsCTClinical Trials
    44. Shah BD, Bishop MR, Oluwole OO, Logan AC, Baer MR, Donnellan WB, O'Dwyer KM, Holmes H, Arellano ML, Ghobadi A, Pagel JM, Lin Y, Cassaday RD, Park JH, Abedi M, Castro JE, DeAngelo DJ, Malone AK, Mawad R, Schiller GJ, Rossi JM, Bot A, Shen T, Goyal L, Jain RK, Vezan R, Wierda WG. KTE-X19 anti-CD19 CAR T-cell therapy in adult relapsed/refractory acute lymphoblastic leukemia: ZUMA-3 phase 1 results. Blood. 2021 07 08; 138(1):11-22. PMID: 33827116; PMCID: PMC9999039.
      Citations: 85     Fields:    Translation:HumansCTClinical Trials
    45. Singh N, Singh A, Besser SA, Lang RM, Mor-Avi V, Kosuri S, Bishop MR, DeCara JM. Echocardiographic predictors of new-onset atrial arrhythmias in patients undergoing hematopoietic stem cell transplantation. Int J Cardiol. 2021 Sep 15; 339:225-231. PMID: 34174337.
      Citations:    Fields:    Translation:Humans
    46. Trujillo JA, Godfrey J, Hu Y, Huang J, Smith SM, Frigault MJ, DeFilipp Z, Appelbaum D, Pu Y, Feinberg N, Althaus T, Bishop MR, Riedell PA, Kline J. Primary resistance to CD19-directed chimeric antigen receptor T-cell therapy in T-cell/histiocyte-rich large B-cell lymphoma. Blood. 2021 06 17; 137(24):3454-3459. PMID: 33881502; PMCID: PMC8212512.
      Citations: 12     Fields:    Translation:HumansCells
    47. Cornell RF, Bishop MR, Kumar S, Giralt SA, Nooka AK, Larson SM, Locke FL, Raje NS, Lei L, Dong J, Le Gall JB, Rossi JM, Orlowski RZ. A phase 1, multicenter study evaluating the safety and efficacy of KITE-585, an autologous anti-BCMA CAR T-cell therapy, in patients with relapsed/refractory multiple myeloma. Am J Cancer Res. 2021; 11(6):3285-3293. PMID: 34249462; PMCID: PMC8263642.
      Citations: 7     
    48. Harris K, LaBelle JL, Bishop MR. Current Status of CAR T Cell Therapy for Leukemias. Curr Treat Options Oncol. 2021 06 07; 22(7):62. PMID: 34097135.
      Citations: 13     Fields:    Translation:Humans
    49. Shah BD, Ghobadi A, Oluwole OO, Logan AC, Boissel N, Cassaday RD, Leguay T, Bishop MR, Topp MS, Tzachanis D, O'Dwyer KM, Arellano ML, Lin Y, Baer MR, Schiller GJ, Park JH, Subklewe M, Abedi M, Minnema MC, Wierda WG, DeAngelo DJ, Stiff P, Jeyakumar D, Feng C, Dong J, Shen T, Milletti F, Rossi JM, Vezan R, Masouleh BK, Houot R. KTE-X19 for relapsed or refractory adult B-cell acute lymphoblastic leukaemia: phase 2 results of the single-arm, open-label, multicentre ZUMA-3 study. Lancet. 2021 08 07; 398(10299):491-502. PMID: 34097852; PMCID: PMC11613962.
      Citations: 301     Fields:    Translation:HumansCTClinical Trials
    50. Lacy M, Fong M, Bolton C, Maranzano M, Bishop M, Artz A. Cognitive functioning of older adults prior to hematopoietic stem cell transplantation. Bone Marrow Transplant. 2021 10; 56(10):2575-2581. PMID: 34031555.
      Citations: 2     Fields:    Translation:Humans
    51. Major A, Collins J, Craney C, Heitman AK, Bauer E, Zerante E, Stock W, Bishop MR, Jasielec J. Management of hemophagocytic lymphohistiocytosis (HLH) associated with chimeric antigen receptor T-cell (CAR-T) therapy using anti-cytokine therapy: an illustrative case and review of the literature. Leuk Lymphoma. 2021 07; 62(7):1765-1769. PMID: 33559517; PMCID: PMC8282706.
      Citations: 21     Fields:    Translation:HumansCells
    52. Riedell PA, Wu M, Collins JM, Gideon JM, Jakubowiak AJ, Kline JP, Kosuri S, Liu H, Smith SM, Bishop MR. Bloodless chimeric antigen receptor (CAR) T-cell therapy in Jehovah's Witnesses. Leuk Lymphoma. 2021 06; 62(6):1497-1501. PMID: 33535838.
      Citations:    Fields:    Translation:Humans
    53. Riedell PA, Kline JP, Gideon JM, Wickrema A, Bishop MR. Navigating Dilemmas in Treatment Choice: Our Approach to Supplemental Apheresis Prior to Enrollment in Early- Phase Cellular Therapy Clinical Trials. Transplant Cell Ther. 2021 02; 27(2):105-107. PMID: 33781544.
      Citations:    Fields:    
    54. Maus MV, Alexander S, Bishop MR, Brudno JN, Callahan C, Davila ML, Diamonte C, Dietrich J, Fitzgerald JC, Frigault MJ, Fry TJ, Holter-Chakrabarty JL, Komanduri KV, Lee DW, Locke FL, Maude SL, McCarthy PL, Mead E, Neelapu SS, Neilan TG, Santomasso BD, Shpall EJ, Teachey DT, Turtle CJ, Whitehead T, Grupp SA. Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune effector cell-related adverse events. J Immunother Cancer. 2020 12; 8(2). PMID: 33335028; PMCID: PMC7745688.
      Citations: 109     Fields:    Translation:Humans
    55. Neelapu SS, Adkins S, Ansell SM, Brody J, Cairo MS, Friedberg JW, Kline JP, Levy R, Porter DL, van Besien K, Werner M, Bishop MR. Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of lymphoma. J Immunother Cancer. 2020 12; 8(2). PMID: 33361336; PMCID: PMC7768967.
      Citations: 11     Fields:    Translation:Humans
    56. Derman BA, Kordas K, Molloy E, Chow S, Dale W, Jakubowiak AJ, Jasielec J, Kline JP, Kosuri S, Lee SM, Liu H, Riedell PA, Smith SM, Bishop MR, Artz AS. Recommendations and outcomes from a geriatric assessment guided multidisciplinary clinic prior to autologous stem cell transplant in older patients. J Geriatr Oncol. 2021 05; 12(4):585-591. PMID: 33162369.
      Citations: 6     Fields:    Translation:Humans
    57. Kanelidis AJ, Raikhelkar J, Kim G, Sayer G, Bishop MR, Polonsky TS, Uriel N. CardioMEMS-Guided CAR T Cell Therapy for Lymphoma in a Patient With Anthracycline-Induced Cardiomyopathy. JACC CardioOncol. 2020 Sep; 2(3):515-518. PMID: 34396261; PMCID: PMC8352178.
      Citations: 3     
    58. Varma A, Kosuri S, Ustun C, Ibrahim U, Moreira J, Bishop MR, Nathan S, Mehta J, Moncayo D, Heng J, Osman K, Adekola KUA. COVID-19 infection in hematopoietic cell transplantation: age, time from transplant and steroids matter. Leukemia. 2020 10; 34(10):2809-2812. PMID: 32801310; PMCID: PMC7427757.
      Citations: 32     Fields:    Translation:HumansCellsPHPublic Health
    59. Bishop MR. Optimizing Administration of CAR T-Cell Therapy During the COVID-19 Pandemic. Clin Adv Hematol Oncol. 2020 07; 18(7):400-403. PMID: 32903251.
      Citations: 4     Fields:    Translation:HumansCellsPHPublic Health
    60. Bishop MR. The benefit of CAR T cells in older patients. Blood. 2020 06 04; 135(23):2020-2021. PMID: 32497222.
      Citations: 3     Fields:    Translation:HumansCells
    61. Cooperrider JH, Fulton N, Artz AS, Larson RA, Stock W, Kosuri S, Bishop M, Liu H. Phase I trial of maintenance selinexor after allogeneic hematopoietic stem cell transplantation for patients with acute myeloid leukemia and myelodysplastic syndrome. Bone Marrow Transplant. 2020 11; 55(11):2204-2206. PMID: 32376970.
      Citations: 4     Fields:    Translation:HumansCTClinical Trials
    62. Bachanova V, Bishop MR, Dahi P, Dholaria B, Grupp SA, Hayes-Lattin B, Janakiram M, Maziarz RT, McGuirk JP, Nastoupil LJ, Oluwole OO, Perales MA, Porter DL, Riedell PA, CAR T-cell Consortium. Chimeric Antigen Receptor T Cell Therapy During the COVID-19 Pandemic. Biol Blood Marrow Transplant. 2020 07; 26(7):1239-1246. PMID: 32298807; PMCID: PMC7194685.
      Citations: 41     Fields:    Translation:HumansCellsPHPublic Health
    63. Maziarz RT, Waller EK, Jaeger U, Fleury I, McGuirk J, Holte H, Jaglowski S, Schuster SJ, Bishop MR, Westin JR, Mielke S, Teshima T, Bachanova V, Foley SR, Borchmann P, Salles GA, Zhang J, Tiwari R, Pacaud LB, Ma Q, Tam CS. Patient-reported long-term quality of life after tisagenlecleucel in relapsed/refractory diffuse large B-cell lymphoma. Blood Adv. 2020 02 25; 4(4):629-637. PMID: 32074277; PMCID: PMC7042998.
      Citations: 32     Fields:    Translation:Humans
    64. Wang AY, Kline J, Stock W, Kosuri S, Artz A, Larson RA, Riedell PA, Bishop M, Liu H. Unexpected Toxicities When Nivolumab Was Given as Maintenance Therapy following Allogeneic Stem Cell Transplantation. Biol Blood Marrow Transplant. 2020 05; 26(5):1025-1027. PMID: 32018063.
      Citations: 18     Fields:    Translation:Humans
    65. Riedell PA, Bishop MR. Safety and efficacy of axicabtagene ciloleucel in refractory large B-cell lymphomas. Ther Adv Hematol. 2020; 11:2040620720902899. PMID: 32064069; PMCID: PMC6990602.
      Citations: 8     
    66. Kothari S, Artz AS, Lee SM, Fulton N, Park JH, Stock W, Larson RA, Odenike O, Kline J, LaBelle J, Kosuri S, Riedell P, Nakamura Y, Bishop MR, Liu H. Dose escalation prophylactic donor lymphocyte infusion after T-cell depleted matched related donor allogeneic hematopoietic cell transplantation is feasible and results in higher donor chimerism, faster immune re-constitution, and prolonged progression-free survival. Bone Marrow Transplant. 2020 06; 55(6):1161-1168. PMID: 31992847.
      Citations: 9     Fields:    Translation:HumansCellsCTClinical Trials
    67. Derman BA, Zha Y, Zimmerman TM, Malloy R, Jakubowiak A, Bishop MR, Kline J. Regulatory T-cell depletion in the setting of autologous stem cell transplantation for multiple myeloma: pilot study. J Immunother Cancer. 2020 01; 8(1). PMID: 31940591; PMCID: PMC7057425.
      Citations: 9     Fields:    Translation:HumansCells
    68. Derman BA, Kordas K, Ridgeway J, Chow S, Dale W, Lee SM, Aguada E, Jakubowiak AJ, Jasielec J, Kline J, Kosuri S, Larson RA, Liu H, Mortel M, Odenike O, Pisano J, Riedell P, Stock W, Bishop MR, Artz AS. Results from a multidisciplinary clinic guided by geriatric assessment before stem cell transplantation in older adults. Blood Adv. 2019 11 26; 3(22):3488-3498. PMID: 31725894; PMCID: PMC6880895.
      Citations: 33     Fields:    Translation:Humans
    69. Dalton H, Read DMY, Booth A, Perkins D, Goodwin N, Hendry A, Handley T, Davies K, Bishop M, Sheather-Reid R, Bradfield S, Lewis P, Gazzard T, Critchley A, Wilcox S. Formative Evaluation of the Central Coast Integrated Care Program (CCICP), NSW Australia. Int J Integr Care. 2019 Aug 27; 19(3):15. PMID: 31523219; PMCID: PMC6715937.
      Citations: 9     
    70. Bishop MR. The case for CAR T-cell therapy in follicular lymphomas. Blood. 2019 08 15; 134(7):577-578. PMID: 31416814.
      Citations: 7     Fields:    Translation:HumansCells
    71. Misra MK, Xin JJ, Brown NK, Weidner JG, Upchurch RL, Bishop MR, Wool GD, Artz AS, Marino SR. Effective desensitization for a strong donor-specific HLA antibody in a case of HLA-mismatched allogeneic hematopoietic cell transplantation. HLA. 2019 09; 94(3):307-311. PMID: 31314169.
      Citations: 1     Fields:    Translation:Humans
    72. Bishop MR, Maziarz RT, Waller EK, Jäger U, Westin JR, McGuirk JP, Fleury I, Holte H, Borchmann P, Del Corral C, Tiwari R, Anak Ö, Awasthi R, Pacaud L, Romanov VV, Schuster SJ. Tisagenlecleucel in relapsed/refractory diffuse large B-cell lymphoma patients without measurable disease at infusion. Blood Adv. 2019 07 23; 3(14):2230-2236. PMID: 31332046; PMCID: PMC6650727.
      Citations: 41     Fields:    Translation:Humans
    73. van Besien K, Artz A, Champlin RE, Guarneri D, Bishop MR, Chen J, Gergis U, Shore T, Liu H, Rondon G, Mayer SA, Srour SA, Stock W, Ciurea SO. Haploidentical vs haplo-cord transplant in adults under 60 years receiving fludarabine and melphalan conditioning. Blood Adv. 2019 06 25; 3(12):1858-1867. PMID: 31217161; PMCID: PMC6595267.
      Citations: 12     Fields:    Translation:HumansCellsCTClinical Trials
    74. Jeong JJ, Gu X, Nie J, Sundaravel S, Liu H, Kuo WL, Bhagat TD, Pradhan K, Cao J, Nischal S, McGraw KL, Bhattacharyya S, Bishop MR, Artz A, Thirman MJ, Moliterno A, Ji P, Levine RL, Godley LA, Steidl U, Bieker JJ, List AF, Saunthararajah Y, He C, Verma A, Wickrema A. Cytokine-Regulated Phosphorylation and Activation of TET2 by JAK2 in Hematopoiesis. Cancer Discov. 2019 06; 9(6):778-795. PMID: 30944118; PMCID: PMC6697164.
      Citations: 35     Fields:    Translation:HumansCells
    75. Gilmore BA, Rodby RA, Cimbaluk D, Venugopal P, Patel P, Barton K, Hagen P, Rodriguez T, Sumoza L, Bishop MR, Dhakal B, Hari P, Paner A. When Monoclonal Gammopathy is of Renal Significance: A Case Study of Crystalglobulinemia From Chicago Multiple Myeloma Rounds. Clin Lymphoma Myeloma Leuk. 2019 06; 19(6):e251-e258. PMID: 30987953.
      Citations: 4     Fields:    Translation:Humans
    76. Godfrey JK, Nabhan C, Karrison T, Kline JP, Cohen KS, Bishop MR, Stadler WM, Karmali R, Venugopal P, Rapoport AP, Smith SM. Phase 1 study of lenalidomide plus dose-adjusted EPOCH-R in patients with aggressive B-cell lymphomas with deregulated MYC and BCL2. Cancer. 2019 06 01; 125(11):1830-1836. PMID: 30707764.
      Citations: 12     Fields:    Translation:HumansCTClinical Trials
    77. Fan Y, Artz AS, van Besien K, Stock W, Larson RA, Odenike O, Godley LA, Kline J, Cunningham JM, LaBelle JL, Bishop MR, Liu H. Outcomes following second allogeneic stem cell transplant for disease relapse after T cell depleted transplant correlate with remission status and remission duration after the first transplant. Exp Hematol Oncol. 2019; 8:1. PMID: 30622841; PMCID: PMC6317199.
      Citations: 5     
    78. Boyiadzis MM, Dhodapkar MV, Brentjens RJ, Kochenderfer JN, Neelapu SS, Maus MV, Porter DL, Maloney DG, Grupp SA, Mackall CL, June CH, Bishop MR. Chimeric antigen receptor (CAR) T therapies for the treatment of hematologic malignancies: clinical perspective and significance. J Immunother Cancer. 2018 12 04; 6(1):137. PMID: 30514386; PMCID: PMC6278156.
      Citations: 117     Fields:    Translation:HumansAnimalsCells
    79. Schuster SJ, Bishop MR, Tam CS, Waller EK, Borchmann P, McGuirk JP, Jäger U, Jaglowski S, Andreadis C, Westin JR, Fleury I, Bachanova V, Foley SR, Ho PJ, Mielke S, Magenau JM, Holte H, Pantano S, Pacaud LB, Awasthi R, Chu J, Anak Ö, Salles G, Maziarz RT, JULIET Investigators. Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma. N Engl J Med. 2019 01 03; 380(1):45-56. PMID: 30501490.
      Citations: 1760     Fields:    Translation:HumansCTClinical Trials
    80. D'Angelo CR, Novitsky B, Mee Lee S, Godley LA, Kline J, Larson RA, Liu H, Odenike O, Stock W, Bishop MR, Artz AS. Characterization of cancer comorbidity prior to allogeneic hematopoietic cell transplantation. Leuk Lymphoma. 2019 03; 60(3):629-638. PMID: 30070150.
      Citations: 2     Fields:    Translation:Humans
    81. Chen YB, McCarthy PL, Hahn T, Holstein SA, Ueda M, Kröger N, Bishop M, de Lima M. Methods to prevent and treat relapse after hematopoietic stem cell transplantation with tyrosine kinase inhibitors, immunomodulating drugs, deacetylase inhibitors, and hypomethylating agents. Bone Marrow Transplant. 2019 04; 54(4):497-507. PMID: 30038353.
      Citations: 7     Fields:    Translation:Humans
    82. Gökbuget N, Canaani J, Nagler A, Bishop M, Kröger N, Avigan D. Prevention and treatment of relapse after stem cell transplantation with immunotherapy. Bone Marrow Transplant. 2018 06; 53(6):664-672. PMID: 29795427.
      Citations: 6     Fields:    Translation:Humans
    83. Sureda A, Dreger P, Bishop MR, Kroger N, Porter DL. Prevention and treatment of relapse after stem cell transplantation in lymphoid malignancies. Bone Marrow Transplant. 2019 01; 54(1):17-25. PMID: 29795433.
      Citations: 1     Fields:    Translation:Humans
    84. Teachey DT, Bishop MR, Maloney DG, Grupp SA. Toxicity management after chimeric antigen receptor T cell therapy: one size does not fit 'ALL'. Nat Rev Clin Oncol. 2018 04; 15(4):218. PMID: 29434335.
      Citations: 52     Fields:    Translation:Humans
    85. Wang AY, Weiner H, Green M, Chang H, Fulton N, Larson RA, Odenike O, Artz AS, Bishop MR, Godley LA, Thirman MJ, Kosuri S, Churpek JE, Curran E, Pettit K, Stock W, Liu H. A phase I study of selinexor in combination with high-dose cytarabine and mitoxantrone for remission induction in patients with acute myeloid leukemia. J Hematol Oncol. 2018 01 05; 11(1):4. PMID: 29304833; PMCID: PMC5756334.
      Citations: 34     Fields:    Translation:HumansCTClinical Trials
    86. Tsai SB, Rhodes J, Liu H, Shore T, Bishop M, Cushing MM, Gergis U, Godley L, Kline J, Larson RA, Mayer S, Odenike O, Stock W, Wickrema A, van Besien K, Artz AS. Reduced-Intensity Allogeneic Transplant for Acute Myeloid Leukemia and Myelodysplastic Syndrome Using Combined CD34-Selected Haploidentical Graft and a Single Umbilical Cord Unit Compared with Matched Unrelated Donor Stem Cells in Older Adults. Biol Blood Marrow Transplant. 2018 05; 24(5):997-1004. PMID: 29288821.
      Citations: 7     Fields:    Translation:Humans
    87. Hsu J, Artz A, Mayer SA, Guarner D, Bishop MR, Reich-Slotky R, Smith SM, Greenberg J, Kline J, Ferrante R, Phillips AA, Gergis U, Liu H, Stock W, Cushing M, Shore TB, van Besien K. Combined Haploidentical and Umbilical Cord Blood Allogeneic Stem Cell Transplantation for High-Risk Lymphoma and Chronic Lymphoblastic Leukemia. Biol Blood Marrow Transplant. 2018 02; 24(2):359-365. PMID: 29128555; PMCID: PMC6574086.
      Citations: 5     Fields:    Translation:Humans
    88. Riedell PA, Bishop MR. Post-autologous transplant maintenance therapies in lymphoma: current state and future directions. Bone Marrow Transplant. 2018 01; 53(1):11-21. PMID: 28967896.
      Citations: 1     Fields:    Translation:Humans
    89. Cheng YC, Shi Y, Zhang MJ, Brazauskas R, Hemmer MT, Bishop MR, Nieto Y, Stadtmauer E, Ayash L, Gale RP, Lazarus H, Holmberg L, Lill M, Olsson RF, Wirk BM, Arora M, Hari P, Ueno N. Long-Term Outcome of Inflammatory Breast Cancer Compared to Non-Inflammatory Breast Cancer in the Setting of High-Dose Chemotherapy with Autologous Hematopoietic Cell Transplantation. J Cancer. 2017; 8(6):1009-1017. PMID: 28529613; PMCID: PMC5436253.
      Citations: 4     
    90. Godfrey J, Bishop MR, Syed S, Hyjek E, Kline J. PD-1 blockade induces remissions in relapsed classical Hodgkin lymphoma following allogeneic hematopoietic stem cell transplantation. J Immunother Cancer. 2017; 5:11. PMID: 28239465; PMCID: PMC5319147.
      Citations: 19     Fields:    Translation:Humans
    91. Galanina N, Kline J, Bishop MR. Emerging role of checkpoint blockade therapy in lymphoma. Ther Adv Hematol. 2017 Feb; 8(2):81-90. PMID: 28203344; PMCID: PMC5298386.
      Citations: 10     
    92. Boyiadzis M, Bishop MR, Abonour R, Anderson KC, Ansell SM, Avigan D, Barbarotta L, Barrett AJ, Van Besien K, Bergsagel PL, Borrello I, Brody J, Brufsky J, Cairo M, Chari A, Cohen A, Cortes J, Forman SJ, Friedberg JW, Fuchs EJ, Gore SD, Jagannath S, Kahl BS, Kline J, Kochenderfer JN, Kwak LW, Levy R, de Lima M, Litzow MR, Mahindra A, Miller J, Munshi NC, Orlowski RZ, Pagel JM, Porter DL, Russell SJ, Schwartz K, Shipp MA, Siegel D, Stone RM, Tallman MS, Timmerman JM, Van Rhee F, Waller EK, Welsh A, Werner M, Wiernik PH, Dhodapkar MV. The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of hematologic malignancies: multiple myeloma, lymphoma, and acute leukemia. J Immunother Cancer. 2016; 4:90. PMID: 28018601; PMCID: PMC5168808.
      Citations: 14     Fields:    
    93. Haynes L, Kaste SC, Ness KK, Wu J, Ortega-Laureano L, Bishop M, Neel M, Rao B, Fernandez-Pineda I. Pathologic fracture in childhood and adolescent osteosarcoma: A single-institution experience. Pediatr Blood Cancer. 2017 04; 64(4). PMID: 27897381; PMCID: PMC5319893.
      Citations: 4     Fields:    Translation:Humans
    94. Pillai V, Lim MS, Tallarico M, Bishop MR. Mature T- and NK-cell non-Hodgkin lymphoma in children and young adolescents. Br J Haematol. 2016 05; 173(4):573-81. PMID: 26992145.
      Citations: 11     Fields:    Translation:Humans
    95. Tsai SB, Liu H, Shore T, Fan Y, Bishop M, Cushing MM, Gergis U, Godley L, Kline J, Larson RA, Martinez G, Mayer S, Odenike O, Stock W, Wickrema A, van Besien K, Artz AS. Frequency and Risk Factors Associated with Cord Graft Failure after Transplant with Single-Unit Umbilical Cord Cells Supplemented by Haploidentical Cells with Reduced-Intensity Conditioning. Biol Blood Marrow Transplant. 2016 06; 22(6):1065-1072. PMID: 26912055; PMCID: PMC4867292.
      Citations: 8     Fields:    Translation:HumansCTClinical Trials
    96. van Besien K, Hari P, Zhang MJ, Liu HT, Stock W, Godley L, Odenike O, Larson R, Bishop M, Wickrema A, Gergis U, Mayer S, Shore T, Tsai S, Rhodes J, Cushing MM, Korman S, Artz A. Reduced intensity haplo plus single cord transplant compared to double cord transplant: improved engraftment and graft-versus-host disease-free, relapse-free survival. Haematologica. 2016 05; 101(5):634-43. PMID: 26869630; PMCID: PMC5004373.
      Citations: 13     Fields:    Translation:HumansCellsCTClinical Trials
    97. D'Angelo CR, Kocherginsky M, Pisano J, Bishop MR, Godley LA, Kline J, Larson RA, Liu H, Odenike O, Stock W, Artz AS. Incidence and predictors of respiratory viral infections by multiplex PCR in allogeneic hematopoietic cell transplant recipients 50 years and older including geriatric assessment. Leuk Lymphoma. 2016 08; 57(8):1807-13. PMID: 26699199.
      Citations: 11     Fields:    Translation:HumansCells
    98. Churpek JE, Artz A, Bishop M, Liu H, Godley LA. Correspondence Regarding the Consensus Statement from the Worldwide Network for Blood and Marrow Transplantation Standing Committee on Donor Issues. Biol Blood Marrow Transplant. 2016 Jan; 22(1):183-4. PMID: 26478096.
      Citations: 11     Fields:    Translation:Humans
    99. Kline J, Bishop MR. Update on checkpoint blockade therapy for lymphoma. J Immunother Cancer. 2015; 3:33. PMID: 26199729; PMCID: PMC4509696.
      Citations: 6     Fields:    
    100. Mossoba ME, Halverson DC, Kurlander R, Schuver BB, Carpenter A, Hansen B, Steinberg SM, Ali SA, Tageja N, Hakim FT, Gea-Banacloche J, Sportes C, Hardy NM, Hickstein DD, Pavletic SZ, Khuu H, Sabatini M, Stroncek D, Levine BL, June CH, Mariotti J, Rixe O, Fojo AT, Bishop MR, Gress RE, Fowler DH. High-Dose Sirolimus and Immune-Selective Pentostatin plus Cyclophosphamide Conditioning Yields Stable Mixed Chimerism and Insufficient Graft-versus-Tumor Responses. Clin Cancer Res. 2015 Oct 01; 21(19):4312-20. PMID: 26071480; PMCID: PMC4592398.
      Citations: 6     Fields:    Translation:HumansCells
    101. Yew PY, Alachkar H, Yamaguchi R, Kiyotani K, Fang H, Yap KL, Liu HT, Wickrema A, Artz A, van Besien K, Imoto S, Miyano S, Bishop MR, Stock W, Nakamura Y. Quantitative characterization of T-cell repertoire in allogeneic hematopoietic stem cell transplant recipients. Bone Marrow Transplant. 2015 Sep; 50(9):1227-34. PMID: 26052909; PMCID: PMC4559843.
      Citations: 72     Fields:    Translation:HumansCellsCTClinical Trials
    102. Mellers B, Stone E, Murray T, Minster A, Rohrbaugh N, Bishop M, Chen E, Baker J, Hou Y, Horowitz M, Ungar L, Tetlock P. Identifying and cultivating superforecasters as a method of improving probabilistic predictions. Perspect Psychol Sci. 2015 May; 10(3):267-81. PMID: 25987508.
      Citations: 23     Fields:    Translation:Humans
    103. Loh A, Bishop M, Krasin M, Davidoff AM, Langham MR. Long-term physiologic and oncologic outcomes of inferior vena cava thrombosis in pediatric malignant abdominal tumors. J Pediatr Surg. 2015 Apr; 50(4):550-5. PMID: 25840061.
      Citations: 7     Fields:    Translation:Humans
    104. Muffly LS, Kocherginsky M, Stock W, Chu Q, Bishop MR, Godley LA, Kline J, Liu H, Odenike OM, Larson RA, van Besien K, Artz AS. Geriatric assessment to predict survival in older allogeneic hematopoietic cell transplantation recipients. Haematologica. 2014 Aug; 99(8):1373-9. PMID: 24816237; PMCID: PMC4116837.
      Citations: 109     Fields:    Translation:Humans
    105. Bevans MF, Mitchell SA, Barrett JA, Bishop MR, Childs R, Fowler D, Krumlauf M, Prince P, Shelburne N, Wehrlen L, Yang L. Symptom distress predicts long-term health and well-being in allogeneic stem cell transplantation survivors. Biol Blood Marrow Transplant. 2014 Mar; 20(3):387-95. PMID: 24355521; PMCID: PMC3962950.
      Citations: 22     Fields:    Translation:Humans
    106. Liu HT, Liu DH, Huang XJ, Artz A, Bishop MR. Treatments of disease relapse after allogeneic stem cell transplantation focusing on donor lymphocyte infusion. Chin Med J (Engl). 2013 Nov; 126(22):4380-8. PMID: 24238533.
      Citations: 1     Fields:    Translation:Humans
    107. Fisher V, Khuu H, David-Ocampo V, Byrne K, Pavletic S, Bishop M, Fowler DH, Barrett AJ, Stroncek DF. Analysis of the recovery of cryopreserved and thawed CD34+ and CD3+ cells collected for hematopoietic transplantation. Transfusion. 2014 Apr; 54(4):1088-92. PMID: 24117879; PMCID: PMC3983171.
      Citations: 8     Fields:    Translation:HumansCells
    108. Kochenderfer JN, Dudley ME, Carpenter RO, Kassim SH, Rose JJ, Telford WG, Hakim FT, Halverson DC, Fowler DH, Hardy NM, Mato AR, Hickstein DD, Gea-Banacloche JC, Pavletic SZ, Sportes C, Maric I, Feldman SA, Hansen BG, Wilder JS, Blacklock-Schuver B, Jena B, Bishop MR, Gress RE, Rosenberg SA. Donor-derived CD19-targeted T cells cause regression of malignancy persisting after allogeneic hematopoietic stem cell transplantation. Blood. 2013 Dec 12; 122(25):4129-39. PMID: 24055823; PMCID: PMC3862276.
      Citations: 310     Fields:    Translation:HumansCellsCTClinical Trials
    109. Wayne AS, Giralt S, Bishop MR, Kröger N. Proceedings from the National Cancer Institute's Second International Workshop on the Biology, Prevention, and Treatment of Relapse after Hematopoietic Stem Cell Transplantation: introduction. Biol Blood Marrow Transplant. 2013 Nov; 19(11):1534-6. PMID: 24035783; PMCID: PMC3880421.
      Citations: 12     Fields:    Translation:Humans
    110. Avigan D, Hari P, Battiwalla M, Bishop MR, Giralt SA, Hardy NM, Wayne AS, Hsu KC, Kröger N. Proceedings from the National Cancer Institute's Second International Workshop on the Biology, Prevention, and Treatment of Relapse after Hematopoietic Stem Cell Transplantation: part II. Autologous Transplantation-novel agents and immunomodulatory strategies. Biol Blood Marrow Transplant. 2013 Dec; 19(12):1661-9. PMID: 24018393; PMCID: PMC3914636.
      Citations: 6     Fields:    Translation:Humans
    111. de Lima M, Porter DL, Battiwalla M, Bishop MR, Giralt SA, Hardy NM, Wayne AS, Schmid C, Kröger N. Proceedings from the National Cancer Institute's Second International Workshop on the Biology, Prevention, and Treatment of Relapse After Hematopoietic Stem Cell Transplantation: part III. Prevention and treatment of relapse after allogeneic transplantation. Biol Blood Marrow Transplant. 2014 Jan; 20(1):4-13. PMID: 24018392; PMCID: PMC3938421.
      Citations: 67     Fields:    Translation:HumansCellsPHPublic Health
    112. Gress RE, Miller JS, Battiwalla M, Bishop MR, Giralt SA, Hardy NM, Wayne AS, Landau DA, Wu CJ, Kröger N. Proceedings from the National Cancer Institute's Second International Workshop on the Biology, Prevention, and Treatment of Relapse after Hematopoietic Stem Cell Transplantation: Part I. Biology of relapse after transplantation. Biol Blood Marrow Transplant. 2013 Nov; 19(11):1537-45. PMID: 24018395; PMCID: PMC3922045.
      Citations: 13     Fields:    Translation:Humans
    113. Salit RB, Fowler DH, Dean RM, Pavletic SZ, Hakim FT, Steinberg SM, Hardy NT, Sportes C, Gress RE, Bishop MR. Host lymphocyte depletion as a strategy to facilitate early full donor chimerism after reduced-intensity allogeneic stem cell transplantation. Biol Blood Marrow Transplant. 2013 Oct; 19(10):1509-13. PMID: 23948062; PMCID: PMC7511977.
      Citations: 4     Fields:    Translation:Humans
    114. Shaffer BC, Modric M, Stetler-Stevenson M, Arthur DC, Steinberg SM, Liewehr DJ, Fowler DH, Gale RP, Bishop MR, Pavletic SZ. Rapid complete donor lymphoid chimerism and graft-versus-leukemia effect are important in early control of chronic lymphocytic leukemia. Exp Hematol. 2013 Sep; 41(9):772-8. PMID: 23689118; PMCID: PMC3769491.
      Citations: 6     Fields:    Translation:HumansCellsCTClinical Trials
    115. Bishop MR. Donor lymphocyte infusion: beauty is in the eye of the beholder. Biol Blood Marrow Transplant. 2013 Jun; 19(6):849-50. PMID: 23611978.
      Citations: 1     Fields:    Translation:HumansCells
    116. Liu H, Stock W, Bishop MR. Expanded indications for allogeneic stem cell transplantation in patients with myeloid malignancies. Curr Opin Hematol. 2013 Mar; 20(2):115-22. PMID: 23385613.
      Citations: 8     Fields:    Translation:Humans
    117. Fowler DH, Mossoba ME, Steinberg SM, Halverson DC, Stroncek D, Khuu HM, Hakim FT, Castiello L, Sabatino M, Leitman SF, Mariotti J, Gea-Banacloche JC, Sportes C, Hardy NM, Hickstein DD, Pavletic SZ, Rowley S, Goy A, Donato M, Korngold R, Pecora A, Levine BL, June CH, Gress RE, Bishop MR. Phase 2 clinical trial of rapamycin-resistant donor CD4+ Th2/Th1 (T-Rapa) cells after low-intensity allogeneic hematopoietic cell transplantation. Blood. 2013 Apr 11; 121(15):2864-74. PMID: 23426943; PMCID: PMC3624934.
      Citations: 18     Fields:    Translation:HumansCellsCTClinical Trials
    118. Hale GA, Arora M, Ahn KW, He W, Camitta B, Bishop MR, Bitan M, Cairo MS, Chan K, Childs RW, Copelan E, Davies SM, Perez MA, Doyle JJ, Gale RP, Vicent MG, Horn BN, Hussein AA, Jodele S, Kamani NR, Kasow KA, Kletzel M, Lazarus HM, Lewis VA, Myers KC, Olsson R, Pulsipher M, Qayed M, Sanders JE, Shaw PJ, Soni S, Stiff PJ, Stadtmauer EA, Ueno NT, Wall DA, Grupp SA. Allogeneic hematopoietic cell transplantation for neuroblastoma: the CIBMTR experience. Bone Marrow Transplant. 2013 Aug; 48(8):1056-64. PMID: 23419433; PMCID: PMC3661721.
      Citations: 7     Fields:    Translation:Humans
    119. Bacher U, Klyuchnikov E, Le-Rademacher J, Carreras J, Armand P, Bishop MR, Bredeson CN, Cairo MS, Fenske TS, Freytes CO, Gale RP, Gibson J, Isola LM, Inwards DJ, Laport GG, Lazarus HM, Maziarz RT, Wiernik PH, Schouten HC, Slavin S, Smith SM, Vose JM, Waller EK, Hari PN, Lymphoma Working Committee of the CIBMTR. Conditioning regimens for allotransplants for diffuse large B-cell lymphoma: myeloablative or reduced intensity? Blood. 2012 Nov 15; 120(20):4256-62. PMID: 23007405; PMCID: PMC3501720.
      Citations: 62     Fields:    Translation:Humans
    120. Foglietta M, Neelapu SS, Kwak LW, Jiang Y, Nattamai D, Lee ST, Fowler DH, Sportes C, Gress RE, Steinberg SM, Vence LM, Radvanyi L, Dwyer KC, Qazilbash MH, Bryant RN, Bishop MR. Neoantigen and tumor antigen-specific immunity transferred from immunized donors is detectable early after allogeneic transplantation in myeloma patients. Bone Marrow Transplant. 2013 Feb; 48(2):269-77. PMID: 22773122; PMCID: PMC3469751.
      Citations: 7     Fields:    Translation:HumansCellsPHPublic Health
    121. Brinch L, Gedde-Dahl T, Dybedal I, Holte H, Heldal D, Torfoss D, Aurlien E, Lauritzsen GF, Lehne G, Kvalheim G, Egeland T, Bishop MR, Fowler DH, Kolstad A, Fløisand Y, Tjønnfjord GE, Fosså A, Baggerød E. Ultra-short course sirolimus contributes to effective GVHD prophylaxis after reduced-intensity allogeneic hematopoietic cell transplantation. Bone Marrow Transplant. 2012 Dec; 47(12):1552-7. PMID: 22522568; PMCID: PMC6980358.
      Citations: 4     Fields:    Translation:HumansCTClinical Trials
    122. Shah NN, Bacher U, Fry T, Calvo KR, Stetler-Stevenson M, Arthur DC, Kurlander R, Baird K, Wise B, Giralt S, Bishop M, Hardy NM, Wayne AS. Myelodysplastic syndrome after allogeneic hematopoietic stem cell transplantation: diagnostic and therapeutic challenges. Am J Hematol. 2012 Sep; 87(9):916-22. PMID: 22473867; PMCID: PMC3454494.
      Citations: 5     Fields:    Translation:Humans
    123. Cook RJ, Wang Z, Arora M, Lazarus HM, Kasow KA, Champagne MA, Saber W, van Besien KM, Hale GA, Copelan EA, Elmongy M, Ueno NT, Horn BN, Slavin S, Bishop MR, Stadtmauer EA. Clinical outcomes of patients with desmoplastic small round cell tumor of the peritoneum undergoing autologous HCT: a CIBMTR retrospective analysis. Bone Marrow Transplant. 2012 Nov; 47(11):1455-8. PMID: 22465977; PMCID: PMC3951901.
      Citations: 8     Fields:    Translation:Humans
    124. Guerard EJ, Bishop MR. Overview of non-Hodgkin's lymphoma. Dis Mon. 2012 Apr; 58(4):208-18. PMID: 22449369.
      Citations: 6     Fields:    Translation:Humans
    125. Salit RB, Fowler DH, Wilson WH, Dean RM, Pavletic SZ, Dunleavy K, Hakim F, Fry TJ, Steinberg SM, Hughes TE, Odom J, Bryant K, Gress RE, Bishop MR. Dose-adjusted EPOCH-rituximab combined with fludarabine provides an effective bridge to reduced-intensity allogeneic hematopoietic stem-cell transplantation in patients with lymphoid malignancies. J Clin Oncol. 2012 Mar 10; 30(8):830-6. PMID: 22312100; PMCID: PMC3295571.
      Citations: 9     Fields:    Translation:Humans
    126. Hardy NM, Fellowes V, Rose JJ, Odom J, Pittaluga S, Steinberg SM, Blacklock-Schuver B, Avila DN, Memon S, Kurlander RJ, Khuu HM, Stetler-Stevenson M, Mena E, Dwyer AJ, Levine BL, June CH, Reshef R, Vonderheide RH, Gress RE, Fowler DH, Hakim FT, Bishop MR. Costimulated tumor-infiltrating lymphocytes are a feasible and safe alternative donor cell therapy for relapse after allogeneic stem cell transplantation. Blood. 2012 Mar 22; 119(12):2956-9. PMID: 22289893; PMCID: PMC3327466.
      Citations: 11     Fields:    Translation:HumansCellsCTClinical Trials
    127. Bacher U, Talano JA, Bishop MR. Monitoring and prevention of relapse after allogeneic hematopoietic cell transplantation for myeloid malignancies. Biol Blood Marrow Transplant. 2012 Jan; 18(1 Suppl):S62-73. PMID: 22226115.
      Citations: 3     Fields:    Translation:Humans
    128. Hawn MT, Houston TK, Campagna EJ, Graham LA, Singh J, Bishop M, Henderson WG. The attributable risk of smoking on surgical complications. Ann Surg. 2011 Dec; 254(6):914-20. PMID: 21869677.
      Citations: 57     Fields:    Translation:Humans
    129. Hardy NM, Mossoba ME, Steinberg SM, Fellowes V, Yan XY, Hakim FT, Babb RR, Avila D, Gea-Banacloche J, Levine BL, June CH, Khuu HM, Carpenter AE, Krumlauf MC, Dwyer AJ, Gress RE, Fowler DH, Bishop MR, Sportès C. Phase I trial of adoptive cell transfer with mixed-profile type-I/type-II allogeneic T cells for metastatic breast cancer. Clin Cancer Res. 2011 Nov 01; 17(21):6878-87. PMID: 21948234; PMCID: PMC3206984.
      Citations: 6     Fields:    Translation:HumansCellsCTClinical Trials
    130. Baird K, Fry TJ, Steinberg SM, Bishop MR, Fowler DH, Delbrook CP, Humphrey JL, Rager A, Richards K, Wayne AS, Mackall CL. Reduced-intensity allogeneic stem cell transplantation in children and young adults with ultrahigh-risk pediatric sarcomas. Biol Blood Marrow Transplant. 2012 May; 18(5):698-707. PMID: 21896345; PMCID: PMC3262116.
      Citations: 11     Fields:    Translation:HumansCTClinical Trials
    131. Salit RB, Bishop MR. Reduced-intensity allogeneic hematopoietic stem cell transplantation for multiple myeloma: a concise review. Clin Lymphoma Myeloma Leuk. 2011 Jun; 11(3):247-52. PMID: 21658650.
      Citations: 2     Fields:    Translation:Humans
    132. Bevans MF, Mitchell SA, Barrett AJ, Bishop M, Childs R, Fowler D, Krumlauf M, Prince P, Shelburne N, Wehrlen L. Function, adjustment, quality of life and symptoms (FAQS) in allogeneic hematopoietic stem cell transplantation (HSCT) survivors: a study protocol. Health Qual Life Outcomes. 2011 Apr 17; 9:24. PMID: 21496339; PMCID: PMC3101119.
      Citations: 15     Fields:    Translation:Humans
    133. Salit RB, Bishop MR. The evolving world of tumor lysis syndrome. Oncology (Williston Park). 2011 Apr 15; 25(4):378, 380. PMID: 21618961.
      Citations: 1     Fields:    Translation:Humans
    134. Mitchell SA, Jacobsohn D, Thormann Powers KE, Carpenter PA, Flowers ME, Cowen EW, Schubert M, Turner ML, Lee SJ, Martin P, Bishop MR, Baird K, Boyd K, Fall-Dickson JM, Gerber LH, Guadagnini JP, Imanguli M, Krumlauf MC, Lawley L, Li L, Reeve BB, Clayton JA, Vogelsang GB, Pavletic SZ, Bolaños-Meade J. A multicenter pilot evaluation of the National Institutes of Health chronic graft-versus-host disease (cGVHD) therapeutic response measures: feasibility, interrater reliability, and minimum detectable change. Biol Blood Marrow Transplant. 2011 Nov; 17(11):1619-29. PMID: 21536143; PMCID: PMC3158826.
      Citations: 41     Fields:    Translation:Humans
    135. Cohen JI, Jaffe ES, Dale JK, Pittaluga S, Heslop HE, Rooney CM, Gottschalk S, Bollard CM, Rao VK, Marques A, Burbelo PD, Turk SP, Fulton R, Wayne AS, Little RF, Cairo MS, El-Mallawany NK, Fowler D, Sportes C, Bishop MR, Wilson W, Straus SE. Characterization and treatment of chronic active Epstein-Barr virus disease: a 28-year experience in the United States. Blood. 2011 Jun 02; 117(22):5835-49. PMID: 21454450; PMCID: PMC3112034.
      Citations: 124     Fields:    Translation:HumansCells
    136. Luger SM, Zhang MJ, Bishop MR, Bornhauser M, Bredeson CN, Cairo MS, Copelan EA, Gale RP, Giralt SA, Gulbas Z, Gupta V, Hale GA, Lazarus HM, Lewis VA, Lill MC, McCarthy PL, Weisdorf DJ, Pulsipher MA, Ringdén O, Pérez WS. Similar outcomes using myeloablative vs reduced-intensity allogeneic transplant preparative regimens for AML or MDS. Bone Marrow Transplant. 2012 Feb; 47(2):203-11. PMID: 21441963; PMCID: PMC3134582.
      Citations: 112     Fields:    Translation:Humans
    137. Bishop MR, Alyea EP, Cairo MS, Falkenburg JH, June CH, Little RF, Miller JS, Pavletic SZ, Porter DL, Riddell SR, van Besien K, Wayne AS, Weisdorf DJ, Wu RS, Giralt S, Kröger N. National Cancer Institute's First International Workshop on the Biology, Prevention, and Treatment of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation: summary and recommendations from the organizing committee. Biol Blood Marrow Transplant. 2011 Apr; 17(4):443-54. PMID: 21224011; PMCID: PMC3102296.
      Citations: 18     Fields:    Translation:Humans
    138. Miyamura K, Bishop MR, Kröger N. Minimal residual disease following allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2011 Jan; 17(1 Suppl):S94-100. PMID: 21047560; PMCID: PMC3056549.
      Citations: 9     Fields:    
    139. Salit RB, Bishop MR, Pavletic SZ. Allogeneic hematopoietic stem cell transplantation: does it have a place in treating Hodgkin lymphoma? Curr Hematol Malig Rep. 2010 Oct; 5(4):229-38. PMID: 20730513.
      Citations: 4     Fields:    Translation:Humans
    140. Porter DL, Alyea EP, Antin JH, DeLima M, Estey E, Falkenburg JH, Hardy N, Kroeger N, Leis J, Levine J, Maloney DG, Peggs K, Rowe JM, Wayne AS, Giralt S, Bishop MR, van Besien K. NCI First International Workshop on the Biology, Prevention, and Treatment of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation: Report from the Committee on Treatment of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation. Biol Blood Marrow Transplant. 2010 Nov; 16(11):1467-503. PMID: 20699125; PMCID: PMC2955517.
      Citations: 50     Fields:    Translation:Humans
    141. Jamshed S, Fowler DH, Neelapu SS, Dean RM, Steinberg SM, Odom J, Bryant K, Hakim F, Bishop MR. EPOCH-F: a novel salvage regimen for multiple myeloma before reduced-intensity allogeneic hematopoietic SCT. Bone Marrow Transplant. 2011 May; 46(5):676-81. PMID: 20661232; PMCID: PMC6944431.
      Citations: 3     Fields:    
    142. Bacher U, Bader P, Borowitz MJ, Dreger P, Khouri I, Olavarria E, Radich J, Stock W, Vose JM, Weisdorf D, Willasch A, Giralt S, Bishop MR, Wayne AS, Kröger N, Böttcher S. NCI first international workshop on the biology, prevention, and treatment of relapse after allogeneic hematopoietic stem cell transplantation: report from the committee on disease-specific methods and strategies for monitoring relapse following allogeneic stem cell transplantation. part II: chronic leukemias, myeloproliferative neoplasms, and lymphoid malignancies. Biol Blood Marrow Transplant. 2010 Oct; 16(10):1325-46. PMID: 20637879.
      Citations: 10     Fields:    Translation:HumansPHPublic Health
    143. Bacher U, Bader P, Borowitz MJ, Dreger P, Khouri I, Macapinlac HA, Macapintac H, Olavarria E, Radich J, Stock W, Vose JM, Weisdorf D, Willasch A, Giralt S, Bishop MR, Wayne AS, Kröger N, Böttcher S. NCI First International Workshop on the Biology, Prevention, and Treatment of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation: report from the Committee on Disease-Specific Methods and Strategies for Monitoring Relapse following Allogeneic Stem Cell Transplantation. Part I: Methods, acute leukemias, and myelodysplastic syndromes. Biol Blood Marrow Transplant. 2010 Sep; 16(9):1187-211. PMID: 20558311; PMCID: PMC7272718.
      Citations: 26     Fields:    
    144. Alyea EP, DeAngelo DJ, Moldrem J, Pagel JM, Przepiorka D, Sadelin M, Young JW, Giralt S, Bishop M, Riddell S. NCI First International Workshop on The Biology, Prevention and Treatment of Relapse after Allogeneic Hematopoietic Cell Transplantation: report from the committee on prevention of relapse following allogeneic cell transplantation for hematologic malignancies. Biol Blood Marrow Transplant. 2010 Aug; 16(8):1037-69. PMID: 20580849; PMCID: PMC3235046.
      Citations: 23     Fields:    
    145. Pavletic SZ, Kumar S, Mohty M, de Lima M, Foran JM, Pasquini M, Zhang MJ, Giralt S, Bishop MR, Weisdorf D. NCI First International Workshop on the Biology, Prevention, and Treatment of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation: report from the Committee on the Epidemiology and Natural History of Relapse following Allogeneic Cell Transplantation. Biol Blood Marrow Transplant. 2010 Jul; 16(7):871-90. PMID: 20399876; PMCID: PMC2916039.
      Citations: 50     Fields:    
    146. Cairo MS, Jordan CT, Maley CC, Chao C, Melnick A, Armstrong SA, Shlomchik W, Molldrem J, Ferrone S, Mackall C, Zitvogel L, Bishop MR, Giralt SA, June CH. NCI first International Workshop on the biology, prevention, and treatment of relapse after allogeneic hematopoietic stem cell transplantation: report from the committee on the biological considerations of hematological relapse following allogeneic stem cell transplantation unrelated to graft-versus-tumor effects: state of the science. Biol Blood Marrow Transplant. 2010 Jun; 16(6):709-28. PMID: 20227509; PMCID: PMC3711411.
      Citations: 10     Fields:    
    147. Bishop MR, Alyea EP, Cairo MS, Falkenburg JH, June CH, Little RF, Miller JS, Pavletic SZ, Porter D, Riddell SR, van Besien K, Wayne AS, Weisdorf DJ, Wu R, Giralt S, Kröger N. Introduction to the reports from the National Cancer Institute First International Workshop on the Biology, Prevention, and Treatment of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation. Biol Blood Marrow Transplant. 2010 May; 16(5):563-4. PMID: 20202482; PMCID: PMC2996879.
      Citations: 10     Fields:    
    148. Bishop MR, Dean RM, Steinberg SM, Odom J, Pollack SM, Pavletic SZ, Sportes C, Gress RE, Fowler DH. Correlation of pretransplant and early post-transplant response assessment with outcomes after reduced-intensity allogeneic hematopoietic stem cell transplantation for non-Hodgkin's lymphoma. Cancer. 2010 Feb 15; 116(4):852-62. PMID: 20041482; PMCID: PMC6582966.
      Citations: 8     Fields:    
    149. Miller JS, Warren EH, van den Brink MR, Ritz J, Shlomchik WD, Murphy WJ, Barrett AJ, Kolb HJ, Giralt S, Bishop MR, Blazar BR, Falkenburg JH. NCI First International Workshop on The Biology, Prevention, and Treatment of Relapse After Allogeneic Hematopoietic Stem Cell Transplantation: Report from the Committee on the Biology Underlying Recurrence of Malignant Disease following Allogeneic HSCT: Graft-versus-Tumor/Leukemia Reaction. Biol Blood Marrow Transplant. 2010 May; 16(5):565-86. PMID: 20152921; PMCID: PMC2858433.
      Citations: 48     Fields:    
    150. Pulanic D, Cowen EW, Baird K, Bishop MR, Pavletic SZ. Development of severe sclerotic chronic GVHD during treatment with dasatinib. Bone Marrow Transplant. 2010 Sep; 45(9):1469-70. PMID: 20062096; PMCID: PMC7365192.
      Citations: 2     Fields:    
    151. van den Brink MR, Porter DL, Giralt S, Lu SX, Jenq RR, Hanash A, Bishop MR. Relapse after allogeneic hematopoietic cell therapy. Biol Blood Marrow Transplant. 2010 Jan; 16(1 Suppl):S138-45. PMID: 19857588; PMCID: PMC3637945.
      Citations: 43     Fields:    Translation:HumansAnimalsCellsPHPublic Health
    152. Baskar S, Suschak JM, Samija I, Srinivasan R, Childs RW, Pavletic SZ, Bishop MR, Rader C. A human monoclonal antibody drug and target discovery platform for B-cell chronic lymphocytic leukemia based on allogeneic hematopoietic stem cell transplantation and phage display. Blood. 2009 Nov 12; 114(20):4494-502. PMID: 19667400; PMCID: PMC2777128.
      Citations: 13     Fields:    Translation:HumansCells
    153. Steinberg SM, Liewehr DJ, Gea-Banacloche J, Danforth DN, Avila DN, Bryant KE, Krumlauf MC, Fowler DH, Pavletic S, Hardy NM, Bishop MR, Gress RE, Sportès C. Strategies to improve long-term outcome in stage IIIB inflammatory breast cancer: multimodality treatment including dose-intensive induction and high-dose chemotherapy. Biol Blood Marrow Transplant. 2009 Aug; 15(8):963-70. PMID: 19589486; PMCID: PMC2709825.
      Citations: 5     Fields:    Translation:CTClinical Trials
    154. Adelberg DE, Bishop MR. Emergencies related to cancer chemotherapy and hematopoietic stem cell transplantation. Emerg Med Clin North Am. 2009 May; 27(2):311-31. PMID: 19447314.
      Citations: 5     Fields:    Translation:Humans
    155. Pollack SM, Steinberg SM, Odom J, Dean RM, Fowler DH, Bishop MR. Assessment of the hematopoietic cell transplantation comorbidity index in non-Hodgkin lymphoma patients receiving reduced-intensity allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2009 Feb; 15(2):223-30. PMID: 19167682; PMCID: PMC2842937.
      Citations: 10     Fields:    
    156. Giralt S, Bishop MR. Principles and overview of allogeneic hematopoietic stem cell transplantation. Cancer Treat Res. 2009; 144:1-21. PMID: 19779888; PMCID: PMC6953421.
      Citations: 21     Fields:    
    157. Bishop MR. Hematopoietic stem cell transplantation. Introduction. Cancer Treat Res. 2009; 144:ix-x. PMID: 20695131.
      Citations: 2     Fields:    Translation:Humans
    158. Dean RM, Fry T, Mackall C, Steinberg SM, Hakim F, Fowler D, Odom J, Foley J, Gress R, Bishop MR. Association of serum interleukin-7 levels with the development of acute graft-versus-host disease. J Clin Oncol. 2008 Dec 10; 26(35):5735-41. PMID: 19001329; PMCID: PMC2645098.
      Citations: 36     Fields:    Translation:HumansCellsCTClinical Trials
    159. Bishop MR, Dean RM, Steinberg SM, Odom J, Pavletic SZ, Chow C, Pittaluga S, Sportes C, Hardy NM, Gea-Banacloche J, Kolstad A, Gress RE, Fowler DH. Clinical evidence of a graft-versus-lymphoma effect against relapsed diffuse large B-cell lymphoma after allogeneic hematopoietic stem-cell transplantation. Ann Oncol. 2008 Nov; 19(11):1935-40. PMID: 18684698; PMCID: PMC2733078.
      Citations: 29     Fields:    Translation:Humans
    160. Vasu S, Leitman SF, Tisdale JF, Hsieh MM, Childs RW, Barrett AJ, Fowler DH, Bishop MR, Kang EM, Malech HL, Dunbar CE, Khuu HM, Wesley R, Yau YY, Bolan CD. Donor demographic and laboratory predictors of allogeneic peripheral blood stem cell mobilization in an ethnically diverse population. Blood. 2008 Sep 01; 112(5):2092-100. PMID: 18523146; PMCID: PMC2518908.
      Citations: 41     Fields:    
    161. Marks DI, He W, Zhang MJ, Bishop MR, Bolwell BJ, Bredeson CN, Copelan EA, Gale RP, Gupta V, Hale GA, Isola LM, Jakubowski AA, Keating A, Klumpp TR, Lazarus HM, Liesveld JL, Maziarz RT, McCarthy PL, Sabloff M, Schiller G, Sierra J, Tallman MS, Waller EK, Wiernik PH, Weisdorf DJ, Pérez WS. Unrelated donor transplants in adults with Philadelphia-negative acute lymphoblastic leukemia in first complete remission. Blood. 2008 Jul 15; 112(2):426-34. PMID: 18398065; PMCID: PMC2442751.
      Citations: 26     Fields:    Translation:Humans
    162. Boyiadzis M, Memon S, Carson J, Allen K, Szczepanski MJ, Vance BA, Dean R, Bishop MR, Gress RE, Hakim FT. Up-regulation of NK cell activating receptors following allogeneic hematopoietic stem cell transplantation under a lymphodepleting reduced intensity regimen is associated with elevated IL-15 levels. Biol Blood Marrow Transplant. 2008 Mar; 14(3):290-300. PMID: 18275895.
      Citations: 35     Fields:    Translation:HumansCells
    163. Bishop MR, Logan BR, Gandham S, Bolwell BJ, Cahn JY, Lazarus HM, Litzow MR, Marks DI, Wiernik PH, McCarthy PL, Russell JA, Miller CB, Sierra J, Milone G, Keating A, Loberiza FR, Giralt S, Horowitz MM, Weisdorf DJ. Long-term outcomes of adults with acute lymphoblastic leukemia after autologous or unrelated donor bone marrow transplantation: a comparative analysis by the National Marrow Donor Program and Center for International Blood and Marrow Transplant Research. Bone Marrow Transplant. 2008 Apr; 41(7):635-42. PMID: 18084335; PMCID: PMC2587442.
      Citations: 15     Fields:    
    164. Hardy NM, Grady C, Pentz R, Stetler-Stevenson M, Raffeld M, Fontaine LS, Babb R, Bishop MR, Caporaso N, Marti GE. Bioethical considerations of monoclonal B-cell lymphocytosis: donor transfer after haematopoietic stem cell transplantation. Br J Haematol. 2007 Dec; 139(5):824-31. PMID: 18021093.
      Citations: 10     Fields:    Translation:HumansCells
    165. Stratton P, Turner ML, Childs R, Barrett J, Bishop M, Wayne AS, Pavletic S. Vulvovaginal chronic graft-versus-host disease with allogeneic hematopoietic stem cell transplantation. Obstet Gynecol. 2007 Nov; 110(5):1041-9. PMID: 17978118.
      Citations: 22     Fields:    Translation:Humans
    166. Hardy NM, Hakim F, Steinberg SM, Krumlauf M, Cvitkovic R, Babb R, Odom J, Fowler DH, Gress RE, Bishop MR. Host T cells affect donor T cell engraftment and graft-versus-host disease after reduced-intensity hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2007 Sep; 13(9):1022-30. PMID: 17697964; PMCID: PMC2699412.
      Citations: 4     Fields:    
    167. Nava VE, Cohen P, Bishop M, Fowler D, Jaffe ES, Ozdemirli M. Enteropathy-type T-cell lymphoma after intestinal diffuse large B-cell lymphoma. Am J Surg Pathol. 2007 Mar; 31(3):476-80. PMID: 17325491.
      Citations: 3     Fields:    Translation:Humans
    168. Imanguli MM, Atkinson JC, Harvey KE, Hoehn GT, Ryu OH, Wu T, Kingman A, Barrett AJ, Bishop MR, Childs RW, Fowler DH, Pavletic SZ, Hart TC. Changes in salivary proteome following allogeneic hematopoietic stem cell transplantation. Exp Hematol. 2007 Feb; 35(2):184-92. PMID: 17258067; PMCID: PMC1832107.
      Citations: 23     Fields:    
    169. Fotheringham J, Akhyani N, Vortmeyer A, Donati D, Williams E, Oh U, Bishop M, Barrett J, Gea-Banacloche J, Jacobson S. Detection of active human herpesvirus-6 infection in the brain: correlation with polymerase chain reaction detection in cerebrospinal fluid. J Infect Dis. 2007 Feb 01; 195(3):450-4. PMID: 17205485.
      Citations: 33     Fields:    Translation:HumansCells
    170. Yao K, Akyani N, Donati D, Sengamalay N, Fotheringham J, Ghedin E, Bishop M, Barrett J, Kashanchi F, Jacobson S. Detection of HHV-6B in post-mortem central nervous system tissue of a post-bone marrow transplant recipient: a multi-virus array analysis. J Clin Virol. 2006 Dec; 37 Suppl 1:S57-62. PMID: 17276371; PMCID: PMC7128682.
      Citations: 2     Fields:    Translation:HumansCells
    171. Fowler DH, Odom J, Steinberg SM, Chow CK, Foley J, Kogan Y, Hou J, Gea-Banacloche J, Sportes C, Pavletic S, Leitman S, Read EJ, Carter C, Kolstad A, Fox R, Beatty GL, Vonderheide RH, Levine BL, June CH, Gress RE, Bishop MR. Phase I clinical trial of costimulated, IL-4 polarized donor CD4+ T cells as augmentation of allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant. 2006 Nov; 12(11):1150-60. PMID: 17085308.
      Citations: 13     Fields:    Translation:HumansCellsCTClinical Trials
    172. Bevans MF, Marden S, Leidy NK, Soeken K, Cusack G, Rivera P, Mayberry H, Bishop MR, Childs R, Barrett AJ. Health-related quality of life in patients receiving reduced-intensity conditioning allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplant. 2006 Jul; 38(2):101-9. PMID: 16751786.
      Citations: 42     Fields:    Translation:Humans
    173. O'Mahony D, Bishop MR. Monoclonal antibody therapy. Front Biosci. 2006 May 01; 11:1620-35. PMID: 16368542.
      Citations: 13     Fields:    Translation:HumansCells
    174. Hardy NM, Fowler DH, Bishop MR. Immunotherapy of metastatic breast cancer: phase I trail of reduced-intensity allogeneic hematopoietic stem cell transplantation with Th2/Tc2 T-cell exchange. Clin Breast Cancer. 2006 Apr; 7(1):87-9. PMID: 16764750.
      Citations:    Fields:    Translation:HumansCellsCTClinical Trials
    175. Tallman MS, Lazarus HM, Gale RP, Maziarz RT, Rowe JM, Marks DI, Cahn JY, Bashey A, Bishop MR, Christiansen N, Frankel SR, Ilhan O, Laughlin MJ, Liesveld J, Linker C, Litzow MR, Luger S, McCarthy PL, Milone GA, Pavlovsky S, Phillips GL, Russell JA, Saez RA, Schiller G, Sierra J, Weiner RS, Zander AR, Zhang MJ, Keating A, Weisdorf DJ, Horowitz MM, Pérez WS, García JJ. Pretransplantation consolidation chemotherapy decreases leukemia relapse after autologous blood and bone marrow transplants for acute myelogenous leukemia in first remission. Biol Blood Marrow Transplant. 2006 Feb; 12(2):204-16. PMID: 16443518.
      Citations: 4     Fields:    Translation:Humans
    176. Yamashita K, Horwitz ME, Kwatemaa A, Nomicos E, Castro K, Sokolic R, Foster SF, Garofalo M, Choi U, Ryherd M, Brown MR, Leitman SF, Wayne AS, Fowler DH, Bishop MR, Childs RW, Barrett AJ, Pavletic SZ, Malech HL. Unique abnormalities of CD4(+) and CD8(+) central memory cells associated with chronic graft-versus-host disease improve after extracorporeal photopheresis. Biol Blood Marrow Transplant. 2006 Jan; 12(1 Suppl 2):22-30. PMID: 16399598.
      Citations: 3     Fields:    Translation:HumansCellsCTClinical Trials
    177. Dean RM, Fowler DH, Wilson WH, Odom J, Steinberg SM, Chow C, Kasten-Sportes C, Gress RE, Bishop MR. Efficacy of reduced-intensity allogeneic stem cell transplantation in chemotherapy-refractory non-hodgkin lymphoma. Biol Blood Marrow Transplant. 2005 Aug; 11(8):593-9. PMID: 16041309.
      Citations: 11     Fields:    Translation:Humans
    178. Pavletic SZ, Khouri IF, Haagenson M, King RJ, Bierman PJ, Bishop MR, Carston M, Giralt S, Molina A, Copelan EA, Roy V, Ballen K, Adkins DR, McCarthy P, Weisdorf D, Montserrat E, Anasetti C, Ringdén O. Unrelated donor marrow transplantation for B-cell chronic lymphocytic leukemia after using myeloablative conditioning: results from the Center for International Blood and Marrow Transplant research. J Clin Oncol. 2005 Aug 20; 23(24):5788-94. PMID: 16043827.
      Citations: 15     Fields:    Translation:Humans
    179. McCarthy NJ, Hakim F, Steinberg SM, Liewehr DJ, Weng D, Kummar S, Gea-Banacloche J, Chow CK, Dean RM, Castro KM, Marchigiani D, Bishop MR, Fowler DH, Gress RE, Sportès C. Establishing a platform for immunotherapy: clinical outcome and study of immune reconstitution after high-dose chemotherapy with progenitor cell support in breast cancer patients. Biol Blood Marrow Transplant. 2005 Jun; 11(6):472-83. PMID: 15931636.
      Citations: 3     Fields:    Translation:HumansPHPublic HealthCTClinical Trials
    180. Pavletic SZ, Smith LM, Bishop MR, Lynch JC, Tarantolo SR, Vose JM, Bierman PJ, Hadi A, Armitage JO, Kessinger A. Prognostic factors of chronic graft-versus-host disease after allogeneic blood stem-cell transplantation. Am J Hematol. 2005 Apr; 78(4):265-74. PMID: 15795914.
      Citations: 21     Fields:    Translation:Humans
    181. Cairo MS, Bishop M. Tumour lysis syndrome: new therapeutic strategies and classification. Br J Haematol. 2004 Oct; 127(1):3-11. PMID: 15384972.
      Citations: 318     Fields:    Translation:Humans
    182. Bishop MR, Steinberg SM, Gress RE, Hardy NM, Marchigiani D, Kasten-Sportes C, Dean R, Pavletic SZ, Gea-Banacloche J, Castro K, Hakim F, Krumlauf M, Read EJ, Carter C, Leitman SF, Fowler DH. Targeted pretransplant host lymphocyte depletion prior to T-cell depleted reduced-intensity allogeneic stem cell transplantation. Br J Haematol. 2004 Sep; 126(6):837-43. PMID: 15352988.
      Citations: 8     Fields:    Translation:HumansCellsCTClinical Trials
    183. Bishop MR, Fowler DH, Marchigiani D, Castro K, Kasten-Sportes C, Steinberg SM, Gea-Banacloche JC, Dean R, Chow CK, Carter C, Read EJ, Leitman S, Gress R. Allogeneic lymphocytes induce tumor regression of advanced metastatic breast cancer. J Clin Oncol. 2004 Oct 01; 22(19):3886-92. PMID: 15314059.
      Citations: 19     Fields:    Translation:HumansCTClinical Trials
    184. Robinson MR, Lee SS, Rubin BI, Wayne AS, Pavletic SZ, Bishop MR, Childs R, Barrett AJ, Csaky KG. Topical corticosteroid therapy for cicatricial conjunctivitis associated with chronic graft-versus-host disease. Bone Marrow Transplant. 2004 May; 33(10):1031-5. PMID: 15048138.
      Citations: 36     Fields:    Translation:Humans
    185. Bishop MR. Allogeneic hematopoietic stem cell transplantation for metastatic breast cancer. Haematologica. 2004 May; 89(5):599-605. PMID: 15136224.
      Citations: 3     Fields:    Translation:HumansAnimalsCells
    186. Dean RM, Bishop MR. Allogeneic hematopoietic stem cell transplantation for lymphoma. Clin Lymphoma. 2004 Mar; 4(4):238-49. PMID: 15072616.
      Citations:    Fields:    Translation:Humans
    187. Fowler DH, Foley J, Whit-Shan Hou J, Odom J, Castro K, Steinberg SM, Gea-Banacloche J, Kasten-Sportes C, Gress RE, Bishop MR. Clinical "cytokine storm" as revealed by monocyte intracellular flow cytometry: correlation of tumor necrosis factor alpha with severe gut graft-versus-host disease. Clin Gastroenterol Hepatol. 2004 Mar; 2(3):237-45. PMID: 15017608.
      Citations: 13     Fields:    Translation:HumansCells
    188. Yamashita K, Choi U, Woltz PC, Foster SF, Sneller MC, Hakim FT, Fowler DH, Bishop MR, Pavletic SZ, Tamari M, Castro K, Barrett AJ, Childs RW, Illei GG, Leitman SF, Malech HL, Horwitz ME. Severe chronic graft-versus-host disease is characterized by a preponderance of CD4(+) effector memory cells relative to central memory cells. Blood. 2004 May 15; 103(10):3986-8. PMID: 14764530.
      Citations: 26     Fields:    Translation:HumansCells
    189. Kwak LW, Neelapu SS, Bishop MR. Adoptive immunotherapy with antigen-specific T cells in myeloma: a model of tumor-specific donor lymphocyte infusion. Semin Oncol. 2004 Feb; 31(1):37-46. PMID: 14970936.
      Citations: 4     Fields:    Translation:HumansAnimals
    190. Fowler DH, Bishop MR, Gress RE. Immunoablative reduced-intensity stem cell transplantation: potential role of donor Th2 and Tc2 cells. Semin Oncol. 2004 Feb; 31(1):56-67. PMID: 14970938.
      Citations: 2     Fields:    Translation:HumansAnimalsCells
    191. Walshe J, Bishop MR. Factors affecting engraftment of allogeneic hematopoietic stem cells after reduced-intensity conditioning. Cytotherapy. 2004; 6(6):589-2. PMID: 15773022.
      Citations: 1     Fields:    Translation:HumansAnimalsCells
    192. Bishop MR. The graft-versus-lymphoma effect: fact, fiction, or opportunity? J Clin Oncol. 2003 Oct 15; 21(20):3713-5. PMID: 12963698.
      Citations: 3     Fields:    Translation:Humans
    193. Dean RM, Bishop MR. Graft-versus-host disease: emerging concepts in prevention and therapy. Curr Hematol Rep. 2003 Jul; 2(4):287-94. PMID: 12901325.
      Citations: 14     Fields:    Translation:HumansAnimals
    194. Bishop MR. Nonmyeloablative allogeneic hematopoietic stem cell transplantation for metastatic breast cancer. Clin Breast Cancer. 2003 Apr; 4(1):39-45. PMID: 12744757.
      Citations: 1     Fields:    Translation:Humans
    195. Bishop MR, Hou JW, Wilson WH, Steinberg SM, Odom J, Castro K, Kasten-Sportes C, Gea-Banacloche J, Marchigiani D, Gress R, Fowler DH. Establishment of early donor engraftment after reduced-intensity allogeneic hematopoietic stem cell transplantation to potentiate the graft-versus-lymphoma effect against refractory lymphomas. Biol Blood Marrow Transplant. 2003 Mar; 9(3):162-9. PMID: 12652466.
      Citations: 11     Fields:    Translation:HumansCTClinical Trials
    196. Navolanic PM, Pui CH, Larson RA, Bishop MR, Pearce TE, Cairo MS, Goldman SC, Jeha SC, Shanholtz CB, Leonard JP, McCubrey JA. Elitek-rasburicase: an effective means to prevent and treat hyperuricemia associated with tumor lysis syndrome, a Meeting Report, Dallas, Texas, January 2002. Leukemia. 2003 Mar; 17(3):499-514. PMID: 12646938.
      Citations: 18     Fields:    Translation:Humans
    197. Joshi SS, Bishop MR, Lynch JC, Tarantolo SR, Abhyankar S, Bierman PJ, Vose JM, Geller RB, McGuirk J, Foran J, Bociek RG, Hadi A, Day SD, Armitage JO, Kessinger A, Pavletic ZS. Immunological and clinical effects of post-transplant G-CSF versus placebo in T-cell replete allogeneic blood transplant patients: results from a randomized double-blind study. Cytotherapy. 2003; 5(6):542-52. PMID: 14660050.
      Citations: 3     Fields:    Translation:HumansCellsCTClinical Trials
    198. Pusic I, Pavletic SZ, Kessinger A, Tarantolo SR, Bishop MR. Pseudoautologous blood stem cell transplantation for refractory chronic graft-versus-host disease. Bone Marrow Transplant. 2002 Apr; 29(8):709-10. PMID: 12180118.
      Citations: 2     Fields:    Translation:Humans
    199. Weisdorf D, Bishop M, Dharan B, Bolwell B, Cahn JY, Cairo M, Giralt S, Klein J, Lazarus H, Litzow M, Marks D, McCarthy P, Miller C, Milone G, Russell J, Schultz KR, Sierra J, Wiernik P, Keating A, Loberiza F, Kollman C, Horowitz M. Autologous versus allogeneic unrelated donor transplantation for acute lymphoblastic leukemia: comparative toxicity and outcomes. Biol Blood Marrow Transplant. 2002; 8(4):213-20. PMID: 12014810.
      Citations: 7     Fields:    Translation:Humans
    200. Knutson KL, Bishop MR, Schiffman K, Disis ML. Immunotherapy for breast cancer. Cancer Chemother Biol Response Modif. 2002; 20:351-69. PMID: 12703214.
      Citations: 1     Fields:    Translation:HumansAnimals
    201. Sharp JG, Bishop MR, Copple B, Greiner TC, Iversen PL, Jackson JD, Joshi SS, Benner EJ, Mann SL, Rao AK, Vose JM. Oligonucleotide enhanced cytotoxicity of Idarubicin for lymphoma cells. Leuk Lymphoma. 2001 Jul; 42(3):417-27. PMID: 11699407.
      Citations: 2     Fields:    Translation:HumansCells
    202. Stinson TJ, Adams JR, Bishop MR, Kruse S, Tarantolo S, Bennet CL. Economic analysis of a phase III study of G-CSF vs placebo following allogeneic blood stem cell transplantation. Bone Marrow Transplant. 2000 Sep; 26(6):663-6. PMID: 11041569.
      Citations: 8     Fields:    Translation:HumansCTClinical Trials
    203. Bishop MR, Tarantolo SR, Geller RB, Lynch JC, Bierman PJ, Pavletic ZS, Vose JM, Kruse S, Dix SP, Morris ME, Armitage JO, Kessinger A. A randomized, double-blind trial of filgrastim (granulocyte colony-stimulating factor) versus placebo following allogeneic blood stem cell transplantation. Blood. 2000 Jul 01; 96(1):80-5. PMID: 10891434.
      Citations: 25     Fields:    Translation:HumansCellsCTClinical Trials
    204. Bishop MR, Tarantolo SR, Pavletic ZS, Lynch JC, Morris ME, Zacharias D, Armitage JO, Kessinger A. Filgrastim as an alternative to donor leukocyte infusion for relapse after allogeneic stem-cell transplantation. J Clin Oncol. 2000 Jun; 18(11):2269-72. PMID: 10829047.
      Citations: 3     Fields:    Translation:Humans
    205. Pavletic ZS, Arrowsmith ER, Bierman PJ, Goodman SA, Vose JM, Tarantolo SR, Stein RS, Bociek G, Greer JP, Wu CD, Kollath JP, Weisenburger DD, Kessinger A, Wolff SN, Armitage JO, Bishop MR. Outcome of allogeneic stem cell transplantation for B cell chronic lymphocytic leukemia. Bone Marrow Transplant. 2000 Apr; 25(7):717-22. PMID: 10745256.
      Citations: 11     Fields:    Translation:Humans
    206. Bennett CL, Stinson TJ, Laver JH, Bishop MR, Godwin JE, Tallman MS. Cost analyses of adjunct colony stimulating factors for acute leukemia: can they improve clinical decision making. Leuk Lymphoma. 2000 Mar; 37(1-2):65-70. PMID: 10721770.
      Citations: 6     Fields:    Translation:Humans
    207. Mata JE, Bishop MR, Tarantolo SR, Angel CR, Swanson SA, Iversen PL. Evidence of enhanced iron excretion during systemic phosphorothioate oligodeoxynucleotide treatment. J Toxicol Clin Toxicol. 2000; 38(4):383-7. PMID: 10930054.
      Citations: 5     Fields:    Translation:HumansCTClinical Trials
    208. McCarthy NJ, Bishop MR. Nonmyeloablative allogeneic stem cell transplantation: early promise and limitations. Oncologist. 2000; 5(6):487-96. PMID: 11110600.
      Citations: 1     Fields:    Translation:Humans
    209. Bishop MR. The risk of secondary leukemias following autologous stem cell transplantation. Leuk Res. 1999 Mar; 23(3):281-2. PMID: 10071082.
      Citations:    Fields:    Translation:Humans
    210. Brand RE, DiBaise JK, Quigley EM, Gobar LS, Harmon KS, Lynch JC, Bierman PJ, Bishop MR, Tarantolo SR. Gastroparesis as a cause of nausea and vomiting after high-dose chemotherapy and haemopoietic stem-cell transplantation. Lancet. 1998 Dec 19-26; 352(9145):1985. PMID: 9872252.
      Citations: 2     Fields:    Translation:Humans
    211. Iwen PC, Rupp ME, Bishop MR, Rinaldi MG, Sutton DA, Tarantolo S, Hinrichs SH. Disseminated aspergillosis caused by Aspergillus ustus in a patient following allogeneic peripheral stem cell transplantation. J Clin Microbiol. 1998 Dec; 36(12):3713-7. PMID: 9817905; PMCID: PMC105272.
      Citations: 18     Fields:    Translation:HumansAnimals
    212. Joshi SS, Babushkina-Patz NN, Verbik DJ, Gross TG, Tarantolo SR, Kuszynski CA, Pirruccello SJ, Bishop MR, Kessinger A. Antitumor activity of human umbilical cord blood cells: A comparative analysis with peripheral blood and bone marrow cells. Int J Oncol. 1998 Oct; 13(4):791-9. PMID: 9735410.
      Citations: 3     Fields:    Translation:HumansAnimalsCells
    213. Pavletic ZS, Bierman PJ, Vose JM, Bishop MR, Wu CD, Pierson JL, Kollath JP, Weisenburger DD, Kessinger A, Armitage JO. High incidence of relapse after autologous stem-cell transplantation for B-cell chronic lymphocytic leukemia or small lymphocytic lymphoma. Ann Oncol. 1998 Sep; 9(9):1023-6. PMID: 9818078.
      Citations: 9     Fields:    Translation:Humans
    214. van Besien K, Sobocinski KA, Rowlings PA, Murphy SC, Armitage JO, Bishop MR, Chaekal OK, Gale RP, Klein JP, Lazarus HM, McCarthy PL, Raemaekers JM, Reiffers J, Phillips GL, Schattenberg AV, Verdonck LF, Vose JM, Horowitz MM. Allogeneic bone marrow transplantation for low-grade lymphoma. Blood. 1998 Sep 01; 92(5):1832-6. PMID: 9716615.
      Citations: 21     Fields:    Translation:Humans
    215. Pavletic ZS, Joshi SS, Pirruccello SJ, Tarantolo SR, Kollath J, Reed EC, Bierman PJ, Vose JM, Warkentin PI, Gross TG, Nasrati K, Armitage JO, Kessinger A, Bishop MR. Lymphocyte reconstitution after allogeneic blood stem cell transplantation for hematologic malignancies. Bone Marrow Transplant. 1998 Jan; 21(1):33-41. PMID: 9486492; PMCID: PMC7101861.
      Citations: 18     Fields:    Translation:HumansCells
    216. Bishop MR, Jackson JD, Tarantolo SR, O'Kane-Murphy B, Iversen PL, Bayever E, Joshi SM, Sharp JG, Pierson JL, Warkentin PI, Armitage JO, Kessinger A. Ex vivo treatment of bone marrow with phosphorothioate oligonucleotide OL(1)p53 for autologous transplantation in acute myelogenous leukemia and myelodysplastic syndrome. J Hematother. 1997 Oct; 6(5):441-6. PMID: 9368180.
      Citations: 3     Fields:    Translation:HumansCTClinical Trials
    217. Pavletic ZS, Bishop MR, Tarantolo SR, Martin-Algarra S, Bierman PJ, Vose JM, Reed EC, Gross TG, Kollath J, Nasrati K, Jackson JD, Armitage JO, Kessinger A. Hematopoietic recovery after allogeneic blood stem-cell transplantation compared with bone marrow transplantation in patients with hematologic malignancies. J Clin Oncol. 1997 Apr; 15(4):1608-16. PMID: 9193360.
      Citations: 7     Fields:    Translation:Humans
    218. Bishop MR, Tarantolo SR, Jackson JD, Anderson JR, Schmit-Pokorny K, Zacharias D, Pavletic ZS, Pirruccello SJ, Vose JM, Bierman PJ, Warkentin PI, Armitage JO, Kessinger A. Allogeneic-blood stem-cell collection following mobilization with low-dose granulocyte colony-stimulating factor. J Clin Oncol. 1997 Apr; 15(4):1601-7. PMID: 9193359.
      Citations: 1     Fields:    Translation:HumansCells
    219. Bierman PJ, Vose JM, Anderson JR, Bishop MR, Kessinger A, Armitage JO. High-dose therapy with autologous hematopoietic rescue for follicular low-grade non-Hodgkin's lymphoma. J Clin Oncol. 1997 Feb; 15(2):445-50. PMID: 9053464.
      Citations: 16     Fields:    Translation:Humans
    220. Bishop MR, Kessinger A. Blood stem cell transplantation in non-Hodgkin's lymphoma. Cancer Invest. 1997; 15(2):138-42. PMID: 9095209.
      Citations:    Fields:    Translation:Humans
    221. Bishop MR. Potential use of hematopoietic stem cells after radiation injury. Stem Cells. 1997; 15 Suppl 2:305-10. PMID: 9368317.
      Citations: 2     Fields:    Translation:HumansPHPublic Health
    222. Bishop MR, Henslee-Downey PJ, Anderson JR, Romond EH, Marciniak E, Yankey R, Reeves M, Thompson JS. Long-term survival in advanced chronic myelogenous leukemia following bone marrow transplantation from haploidentical related donors. Bone Marrow Transplant. 1996 Oct; 18(4):747-53. PMID: 8899190.
      Citations: 3     Fields:    Translation:HumansAnimals
    223. Vose JM, Bierman PJ, Ruby E, Reed EC, Bishop MR, Tarantolo S, Kessinger A, Armitage JO. Use of continuous infusion granulocyte-macrophage colony-stimulating factor alone or followed by granulocyte colony-stimulating factor to enhance engraftment following high-dose chemotherapy and autologous bone marrow transplantation for lymphoid malignancies. Bone Marrow Transplant. 1996 Jun; 17(6):951-6. PMID: 8807099.
      Citations:    Fields:    Translation:HumansCTClinical Trials
    224. Pavletic ZS, Bishop MR, Markopoulou K, Wszolek ZK. Drug-induced parkinsonism after allogeneic bone marrow transplantation. Bone Marrow Transplant. 1996 Jun; 17(6):1185-7. PMID: 8807135.
      Citations: 1     Fields:    Translation:Humans
    225. Bishop MR, Iversen PL, Bayever E, Sharp JG, Greiner TC, Copple BL, Ruddon R, Zon G, Spinolo J, Arneson M, Armitage JO, Kessinger A. Phase I trial of an antisense oligonucleotide OL(1)p53 in hematologic malignancies. J Clin Oncol. 1996 Apr; 14(4):1320-6. PMID: 8648390.
      Citations: 14     Fields:    Translation:HumansCTClinical Trials
    226. Bierman PJ, Anderson JR, Freeman MB, Vose JM, Kessinger A, Bishop MR, Armitage JO. High-dose chemotherapy followed by autologous hematopoietic rescue for Hodgkin's disease patients following first relapse after chemotherapy. Ann Oncol. 1996 Feb; 7(2):151-6. PMID: 8777171.
      Citations: 9     Fields:    Translation:HumansCTClinical Trials
    227. Martin-Algarra S, Bishop MR, Tarantolo S, Cowles MK, Reed E, Anderson JR, Vose JM, Bierman P, Armitage JO, Kessinger A. Hematopoietic growth factors after HLA-identical allogeneic bone marrow transplantation in patients treated with methotrexate-containing graft-vs.-host disease prophylaxis. Exp Hematol. 1995 Dec; 23(14):1503-8. PMID: 8542938.
      Citations: 1     Fields:    Translation:Humans
    228. Darrington DL, Vose JM, Anderson JR, Bierman PJ, Bishop MR, Chan WC, Morris ME, Reed EC, Sanger WG, Tarantolo SR, et al. Incidence and characterization of secondary myelodysplastic syndrome and acute myelogenous leukemia following high-dose chemoradiotherapy and autologous stem-cell transplantation for lymphoid malignancies. J Clin Oncol. 1994 Dec; 12(12):2527-34. PMID: 7989926.
      Citations: 25     Fields:    Translation:Humans
    229. Bayever E, Iversen PL, Bishop MR, Sharp JG, Tewary HK, Arneson MA, Pirruccello SJ, Ruddon RW, Kessinger A, Zon G, et al. Systemic administration of a phosphorothioate oligonucleotide with a sequence complementary to p53 for acute myelogenous leukemia and myelodysplastic syndrome: initial results of a phase I trial. Antisense Res Dev. 1993; 3(4):383-90. PMID: 8155979.
      Citations: 31     Fields:    Translation:HumansCellsCTClinical Trials
    230. Bishop MR, Bierman PJ, Vose JM, Armitage JO. The role of high-dose therapy with hematopoietic stem cell rescue in low-grade non-Hodgkin's lymphoma. Ann Oncol. 1993; 4 Suppl 1:1-6. PMID: 8101723.
      Citations: 1     Fields:    Translation:Humans
    Bishop's Networks
    Click the
    Explore
    buttons for more information and interactive visualizations!
    Concepts (574)
    Explore
    _
    Co-Authors (61)
    Explore
    _
    Similar People (60)
    Explore
    _
    Same Department Expand Description
    Explore
    _
    Physical Neighbors
    _